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Abstract 
 
Background: Helminth and malaria co-infections have been hypothesized to be factors 
driving the HIV-1 epidemic in Africa, and the fact that both cause anaemia highlights the 
importance of addressing the interactions between HIV/AIDS, malaria and intestinal 
helminthic infections in pregnancy for individuals in resource limited settings. 
Aims: The aims of this thesis were to determine the prevalence and risk factors for malaria-
helminthic dual infections among HIV positive pregnant women on antiretroviral therapy in 
Rwanda. The second aim was to determine the effect of deworming on immune markers of 
HIV/AIDs disease progression among HIV-infected pregnant women on antiretroviral 
therapy (ART), and to elucidate the benefits of deworming, specifically in targeted versus 
untargeted deworming. 
Methods: A cross-sectional study was carried out in 328 HIV-positive pregnant women 
receiving ART. We determined the prevalence of helminth and malaria dual infections and 
the effects of ART on these infections were also examined. This cross sectional study acted 
as a pilot study for a deworming intervention, which took the form of a longitudinal study of 
targeted and untargeted deworming in which 980 HIV-infected pregnant women were 
randomized to ‘targeted’ and ‘untargeted’ arms with albendazole therapy. The effects of 
deworming on the prevalence of helminth infection and CD4 counts, viral load and 
haemoglobin levels were measured over time at 4 visits. Measurements were at baseline and 
every 3 months thereafter. The presence of Plasmodium falciparum was tested at each visit 
and anti-malarial therapy (Coartem: artemether-lumefantrine) was administered to all 
subjects who tested positive for P. falciparum. Baseline data was used to determine the risk 
factors for helminth infection. Helminthic infection was diagnosed using the Kato Katz 
method, whilst the presence of P. falciparum was identified from blood smears. The CD4 
counts and viral load levels were also determined using standard laboratory methods. 
Results: Within the pilot study of 328 women residing in rural (n=166) and peri-urban 
(n=162) locations, 38% of those tested harboured helminths, 21% had malaria and 10% were 
infected with both. The most prevalent helminth species were Ascaris lumbricoides (20.7%), 
followed by Trichiuris trichiura (9.2%), Ancylostoma duodenale and Necator Americanus 
(1.2%). Helminth infections were characterized by low haemoglobin levels and low CD4 
E. Ivan PhD thesis  Page iii 
 
counts. Subjects treated with a d4T-3TC-NVP regimen had a reduced risk of Trichuris 
trichiura infection (OR, 0.27; 95% CIs, 0.10-0.76; p<0.05) and malaria-helminth dual 
infection (OR, 0.29; 95% CI, 0.11-0.75; p<0.05) compared to those receiving AZT-3TC-NVP 
therapy. Within the longitudinal study of deworming in 980 pregnant, HIV-infected females, 
analysis of the baseline data showed that education and employment reduced the risk of all 
types of infection whilst hand washing protected against helminth infection (0.29 [0.19-0.46]; 
p<0.0005). Logistic regression analysis, at baseline (odds ratio [95% CIs]), demonstrated that 
TDF-3TC-NVP (3.47 [2.21-5.45]; p<0.0005), D4T-3TC-NVP (2.47 [1.27-4.80]; p<0.05) and 
AZT-NVP (2.60 [1.33-5.08]; p<0.05) regimens each yielded higher helminth infection rates 
than the AZT-3TC-NVP regimen. Anti-retroviral therapy had no effect on the risk of malaria. 
The prevalence of P. falciparum infection was similar at all-time points for the targeted and 
non-targeted anti-helminth treatment arms, with a significant fall in helminth prevalence in 
both arms by visit 2. Albendazole therapy was associated with favourable changes in 
haemoglobin levels, CD4 counts and viral loads, in those subjects with helminth infections. 
Haemoglobin levels were similar in both arms at all study visits, rising significantly from 
visit 1 to visit 2 in both groups and peaking by visit 3. Thereafter, levels fell significantly 
(p<0.0005 for both comparisons) by visit 4. 
Conclusions: The prevalence of helminth infection in HIV infected pregnant women on 
antiretroviral therapy is common in rural and peri-urban settings in Rwanda. This study 
clearly shows that, albendazole treatment is associated with an increase in CD4 counts, a fall 
in viral loads and an increase in haemoglobin levels. The effects of albendazole are mediated 
by the eradication of helminth infection. The study also shows that treatment with 
albendazole using a targeted or non-targeted regimen is equally effective. The mechanism by 
which certain ART regimens reduce the risk of helminth infection warrants further study. 
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Preface 
 
This thesis arises from the author’s experience and close observations regarding the paucity 
of data on malaria, helminths among neglected tropical diseases (NTDs) and HIV co-
infections in Rwanda. This was during work co-ordinating the teaching of laboratory students 
and supervising projects in community outreach modules for rural health centre clinical 
placements for laboratory students at the Kigali Health Institute.  
The aims of this study were: to determine the prevalence and risk factors for helminth-
malaria co-infections in pregnant HIV-positive females receiving ART; to investigate 
whether treatment of helminth infections in HIV infected pregnant women have any 
beneficial effect on HIV disease progression markers, such as viral load and CD4 cell counts; 
to determine the effects of de-worming on haemoglobin levels and body mass index; to 
determine the prevalence of malaria infections in the absence and presence of a helminth 
infection; to determine the efficacy of two de-worming intervention methods i.e. targeted and 
untargeted. 
This thesis is presented in six chapters. Chapter one outlines the general introduction and 
perspectives of the HIV and NTDs co-infections and ends with literature review, Chapter two 
describes the materials and methods used to conduct the study, whereas chapters three, four 
and five describes the results of the study presented in form of published scientific papers to 
various types of peer-reviewed journals. Chapter six gives the conclusions and implications 
of the main results, limitations of the study, recommendations and further studies, and then 
offers concluding remarks about the findings with regard to the study hypotheses and 
objectives of the thesis. Chapters end with combined list of references. All published 
manuscripts are attached as pdf appendices and presented at the end of the thesis 
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1. Chapter 1: Literature Review 
 
1.1. Introduction  
This chapter includes a review of the literature that is relevant to the study. It will cover the 
treatment of soil-transmitted helminths in HIV-infected patients on antiretroviral therapy (ART) 
and the global burden and epidemiology of helminths. Helminthic species, diagnosis and 
treatment with albendazole have also been considered. The role of co-infections in the immunity 
deterioration of HIV-infected individuals and the effects on HIV disease progression are all 
considered. A review of this literature identifies a research gap on which this study has been 
based. This is covered at the end of this chapter with a brief statement on the research question 
covered by my study, and a description of the hypothesis tested, and the aims and objectives of 
the study. 
1.1.1. Helminth infection in HIV/AIDs patients on ARTs 
Helminth infections are well-known to affect human immune system and rarely infect the human 
host in isolation, particularly in the settings of tropical countries, where co-infections with HIV 
virus are extremely common [1–3]. Both helminths and HIV-1 pandemic mainly affects people 
living in resource-constrained settings [2–5]. Infections due to soil-transmitted helminths (STHs) 
are said to have inflicted more than 1 billion individuals from the poorest socio-economic levels 
of the developing countries [2,6–9]. Previous research studies have suggested that helminths co-
infection with HIV-1  may result in a more rapid progression of HIV-1 disease [2,7,10]. 
Helminthic infections make the infected host more susceptible to HIV infection and enhance 
disease progression due to the chronic immune activation.  Co-infections of helminthic parasites 
with HIV may ultimately lead to a more rapid destruction of the host immune system, and 
potentially lead to progression of HIV-1 infection to AIDS [11,12]. A study concluded that 
chronic helminth infection may suppress immune responses directed against HIV-1 and that 
concurrent immune activation may directly lead to more rapid loss of CD4 cells in HIV-1 
infected individuals [13,14,15]. It is important to determine if prevalent helminthic infections 
affect the progression of HIV-1 in co-infected individuals living in disease- endemic countries 
among populations at high risk, such as pregnant women taking highly active antiretroviral 
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therapy (HAART). There is limited data on effects of anthelminthic utilization along with 
antiretroviral drugs among pregnant women in resource-limited countries, where co-infection of 
helminths and malaria is prevalent.  The effects of de-worming on the prevalence of helminth 
infection and the level of malaria and HIV co-infection has been poorly investigated and no 
studies on these outcomes have been udetaken in subjects receiving antiretroviral therapy 
(ARTs). The study aim was to test the hypothesis that treatment for helminths and malaria co-
infections positively affects HIV/AIDS immune progression markers among HIV-infected 
pregnant women on ART, using targeted and untargeted deworming strategies in Rwandan 
antenatal care settings.  
Importantly, in Rwanda, the rollout of antiretroviral therapies is on a large scale, particularly for 
HIV-infected pregnant women. However, information regarding helminthic co-infection with 
HIV in rural and peri-urban settings is currently very limited particularly in the context of the 
recent Rwandan Health Ministry policy on early initiation of ART for pregnant women 
irrespective of CD4 cell count levels [16]. We hypothesise that, HIV co-infection with helminths 
may be common among pregnant women in these settings. To date, the public health relevance 
of anthelminthic use in helminth infected pregnant women on ART in Rwanda have not been 
extensively studied, and data covering the effects of the anthelminthic drug albendazole for 
pregnant women on antiretroviral drugs could be very useful for public health program 
managers. 
1.1.2. The burden and epidemiology of neglected tropical diseases 
The burden of disease estimates are widely used for priority setting in public health [17–19] 
Infections due to soil transmitted helminths and other neglected tropical diseases affects over a 
billion people globally [19–21]. However, the global funding priorities underestimated the  
resources for management and control of neglected tropical diseases and this affects the health 
programs targeting the bottom poor billions affected with high morbidity and mortality rates 
[22]. In many parts of African countries, the public health issues with these ailments have less 
attention from public health managers [19]. Earlier studies have proposed that the only way 
forward is the integration of control efforts, with efficacious programs such as HIV and malaria 
combined to provide a package of diagnostic tools and treatment with drugs against the common, 
neglected tropical diseases underscored in the world health organisation control agenda [23,24]. 
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However, despite the several efforts invested in research, no conclusive evidence linked NTDs 
epidemiological studies with HIV pandemic in areas where helminths and malaria co-infection is 
prevalent to elucidate effects of deworming among pregnant women on ARTs in a targeted and 
untargeted deworming strategy. 
1.1.3. Global perspectives on soil-transmitted helminths 
 Soil-transmitted helminths (STHs) are a group of parasitic metazoan worms, affecting billions of 
people in most poorest populations [25,26]. Soil transmitted helminthic infections are among the 
most common in developing countries, but precise estimates of the populations at risk of 
infection, morbidity and mortality are difficult to determine and careful evaluation of the global 
distribution and disease burden of helminths is essential to determine the cost-effectiveness of 
control and to ensure that control programmes are focused appropriately [23]. In turn, 
understanding the disease burden depends on a summary measure of health as well as reliable 
data on risks of infection, morbidity and mortality [20,23,27]. The cosmopolitan distribution and, 
the public health importance of the common roundworms (Ascaris lumbricoides), whipworms 
(Trichuris trichiura), and hookworms (Necator Americanus or Ancylostoma duodenale) are 
described globally [28,29]. They are considered together because it is common for a single 
individual, especially a child living in a less developed country, to be chronically infected with 
all three worms [30]. This is possible in developing countries where individuals are estimated to 
be earning less than US$2 per day [31].  
Moreover, helminthic infection has been estimated to account for between 5 and 39 million 
disability-adjusted life years, largely attributable to anaemia, stunting, and reduced cognitive 
development in children and this causes debilitating effects in adults and women in their 
reproductive age [17,18,32–34].The current control strategies have focused on preventive 
chemotherapy through mass drug administration (MDA), with albendazole as a single dose of 
400mg [23]. Preventive chemotherapy can greatly reduce morbidity from helminths infection, 
but re-infection typically occurs more rapidly after treatment in settings with poor sanitation 
facilities which calls for frequent treatment strategies [35]. In areas with high burden,  prevalence 
is commonly pooled with worm burden which is the intensity of infection, that is frequently 
determined by the number of eggs per gram (EPGs) of faeces for intestinal helminths and other 
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To summarise the global burden of helminthiasis, Table 1.1 below shows the common NTDs 
affecting mostly populations in developing countries. This sheds more insights on the global 
burden of 13 major NTDs (adapted from reference 36). This data demonstrates that populations 
at high risk include regions of sub-Saharan Africa and cuts across the Americas, South East Asia 
and regions of the Pacific. 
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Table 1.1. The global burden of NTDs [35]  
Disease 
[references]  
Global cases Population 
at risk  
Regions with highest prevalence  
Ascariasis [37,38] 807 million 4.2 billion  East Asia and Pacific Islands, India, Sub Saharan 
Africa, South Asia, China and Caribbean  
Trichuriasis [39] 604 million 3.2 billion Sub Saharan Africa, East Asia –Pacific, Latin 
America, India and South Asia  
Hook worm infection 
[40],[41]  
576 millions 3.2 billion  Sub Saharan Africa, East Asia, India, South Asia 
and Latin America) 
Schistosomiasis 
[20,42]  
207 million 779 million  Sub Saharan Africa, Latin America and 
Caribbean  
Lymphatic Filariasis 
[43] 
120 million 1.3 billion  India, South Asia, East Asia and pacific islands, 
sub Saharan Africa  
Trachoma  [44] 84 million 590 million Sub Saharan Africa, Middle East, North Africa, 
South Asia, East Asia –Pacific  
Onchocerciasis [45] 37 million 90 million  Sub Saharan Africa and Latin America  
Leishmaniosis[46] 12 million 350 million  Latin America 
Chagas’ disease [47] 8-9 million 25 million  Latina America and Caribbean,  
Leprosy[34] 0.4 million NAd* India, Sub Saharan Africa and Latin America 
Bruli Ulcer[48] NA NAd* Sub Saharan Africa  
Human African 
Trypanasomiasis [34] 
0.3 60million  Sub Saharan Africa 
Dracunculiasis [49] 0.01 million NAd* Sub Saharan Africa 
*donates data NOT available
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1.1.4. Effects of helminths and malaria on HIV disease progression  
Sub-Saharan Africa is highly burdened with various infectious diseases such as malaria, and 
those caused by the human immunodeficiency virus (HIV)-1 and intestinal helminths [50-52]. 
The prevalence of helminthic infections in most developing countries is very high, and a quarter 
of the world's population is infected [53,54]. Dual helminthic and HIV-1 co-infections are 
extremely common in Africa [55]. Furthermore, literature indicates that helminthic infections 
play a role in the pathogenesis of HIV-1 infection in Africa, due to their profound effects on the 
host immune system, which makes those infected with helminths more susceptible to HIV-1 
infection and more vulnerable to the disease’s effects [56]. 
Helminthic infections also increase mother-to-child transmission of HIV [57]. Chronic immune 
activation with a dominant T-helper 2 profile is seen as hallmark of chronic helminths infection 
[1,13,14].These immune changes are usually characterised by several alterations in the normal 
immune response, particularly those of the cellular immune response, which accounts for the 
possible effects of chronic helminth infection on the host’s ability to handle HIV and other 
infections such as malaria. In a meta-analysis that analysed all the studies that have investigated 
the effects of treatment of helminthic co-infections on HIV-1 disease progression, five studies 
were identified, of which one was a randomised controlled trial [58]. As a result of the meta-
analysis, the authors concluded that, despite the void in conclusive evidence demonstrating the 
efficacy of anthelminthic treatment in slowing HIV-1 disease progression, there is a negative 
correlation between the treatment of helminth infection and HIV plasma viral load [59].The fact 
that only five studies, out of over 6,000 reviewed studies addressing this issue, were finally 
included in the meta-analysis clearly illustrates the paucity of high-quality data in this area. 
Furthermore, even within this small group of studies, significant differences in methodology and 
evaluation are evident. Thus, the review rightly concludes that there is an urgent need for larger 
and wider studies of this question, and that they should be double-blinded and controlled 
[2,58,60]. Since the publication of this review, there has been one additional report of a study 
performed in Tanzania, which showed that the eradication of filarial infection significantly 
decreased plasma HIV viral load [61].  
An increasing body of evidence indicates that co-infection with neglected tropical diseases 
(NTDs) also adversely affects the natural history and progression of malaria and HIV/AIDS [62]. 
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The immunological interplay between malaria and helminths or malaria and HIV has been 
reported in several studies which highlight the severity of the resulting clinical malaria 
[51,52,63-65]. A study from Malawi shows that women infected with hookworms were at a 
higher risk of having malaria than uninfected women [66] and studies from Thailand show an 
increased susceptibility to malaria in patients with soil-transmitted helminth infections [75]. In 
addition to inducing increased susceptibility to malaria, helminth infections, especially 
hookworms and schistosome infections, exacerbate the anaemia caused by malaria. Studies from 
Kenya show that anaemia resulting from helminths and malaria is profound [67]. Both helminths 
and malaria causes anaemia and anaemia in pregnancy contributes to maternal deaths and may 
also contribute to adverse birth outcomes, including intrauterine growth retardation and 
prematurity, and to prenatal morbidity and mortality [67–70]. In pregnancy, anaemia is also a 
leading contributor to maternal morbidity and mortality, and is associated with shock, risk of 
cardiac failure, decreased ability to work, and adverse prenatal outcomes [67]. In coastal Kenya, 
malaria was identified as the most important cause of anaemia in primigravidae, whereas 
hookworm infection was an important cause of anaemia in multigravidae [71]. By some 
estimates, NTDs are second only to HIV/AIDS as a cause of disease burden, resulting in a loss of 
approximately 57 million disability-adjusted life years (DALYs) annually [72].  
Therefore, the presence of helminths may affect the risk of malaria and severity of the disease; 
and the occurrence of malaria infection may in turn increase the risk of helminths infection and 
related morbidities [72-74]. As a result, the disease due to one of these infections could be 
exacerbated due to co-existence of the other, resulting in synergistic effects on the infected host 
[75-77].. It is well known that HIV infection has extremely detrimental effects on the immune 
system [77,78], resulting in an increased incidence of opportunistic infections among co-infected 
individuals [1,80]. The hypothesis is that, if considered together, helminths among other NTDs 
would represent the fourth most important communicable disease in Africa. Recent data suggest 
that control of NTDs could actually become a powerful tool for combating HIV/AIDs, 
tuberculosis and malaria [20,62,72]. Therefore, achieving success in the global fight against 
HIV/AIDs, tuberculosis and malaria may well require a concurrent attack on these NTDs.  
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1.1.5. HIV Co-infection with NTDS in Rwanda  
The most important risk factor for HIV-1 acquisition in Rwanda is heterosexual mode of 
transmission [81] and most of the HIV-infected women are in their reproductive years [81,82]. 
Co-infection of NTDs with HIV is reported to be common in countries within the east African 
region, and it is widely documented that helminthic and HIV infection have an overlapping 
geographical distribution [3,53,72,81]. Data for helminthic prevalence and co-infection with 
HIV-1 in Rwanda is nonetheless very scarce. Health survey data available indicate that HIV 
prevalence is 3 % [83] Countrywide, there are 207 sites providing public access to highly active 
anti-retroviral therapy (HAART) and there are 130,000 adults currently on HAART, of whom 
32,031 are females. Among 212 501 pregnant women previously HIV tested in antenatal care 
6059 (3.8%) were HIV positive [83]. 
Rwandan data available on the prevalence of helminthic infection is for school-going children, 
indicating a prevalence of 64.5% in eight surveyed districts [84]. However, there are no data 
available on the prevalence of helminthic and helminthic-HIV co-infection in pregnant women 
on ART in Rwanda. The World Health Organization recommends that anthelminthic treatment 
be given to pregnant women after the first trimester (13 weeks) in areas where the prevalence of 
hookworm or other soil-transmitted helminths exceeds 20-30% [7,85]. However, the use of 
antenatal anthelminthic treatments remains uncommon in most developing countries, and 
research into its effects has been limited for common neglected tropical diseases. 
 
1.1.6. Diagnosis, treatment, and management of NTDS 
Accurate methods of diagnosis and optimal strategies to sample the population are essential for 
the reliable mapping and surveillance of infectious diseases [86]. The current standard for 
detection of soil-transmitted helminths (STH) entails use of the Kato-Katz diagnostic method 
[86,87].The reliable mapping, surveillance and evaluation of infectious diseases rely upon two 
key factors: accurate methods of diagnosis and optimal strategies to sample the population. For 
the soil-transmitted helminths (STH: Ascaris lumbricoides, Trichuris trichiura and hookworm), 
the commonly used diagnostic technique is the Kato-Katz method [87]. This technique allows for 
the quantification of intensity of infection on the basis of faecal egg counts[88]. In most endemic 
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countries reliable diagnostic tools are not easily available for disease monitoring and surveillance 
yet very critical components for treatment-related complications [81]. 
Soil-transmitted helminths (STHs), primarily Ascaris, Trichuris and hookworm, inflict a 
substantial morbidity burden on poor populations living in tropical and subtropical regions of 
Africa constituting a big share of the bottom poor population of the world [89]. Chronic STH 
infections can cause intestinal blood loss and nutrient loss and malabsorption, which can result in 
or exacerbate iron deficiency, anaemia and other nutritional deficiencies [89,90]. More than 1 
billion people are infected with at least one STH, and at least 44 million pregnant women are 
infected with hookworm alone [89]. Pregnant women are especially vulnerable to the harmful 
consequences of these parasitic infections due to increased nutritional demands during pregnancy 
[89,90]. It important to control STHs using available mass drug admiration where it exists and to 
keep track records of diseases transmission dynamics for monitoring transmission and identify 
possibilities of interruption [32]. Diagnosis and treatment are partly important in identifying 
disease resurgence [28].However, diagnostic tools in low-resource setting lack sufficient 
laboratory infrastructure, equipment and trained health practitioners [91].This remains a big 
challenge while trying to design control interventions for neglected tropical diseases and other 
comorbidities. Resource limited countries and more at risk of getting infected with dozens of 
nematode worms but have limited control of disease surveillance laboratory capacity [92]. 
Therefore, multiple health interventions approach has the potential to minimise costs and expand 
intervention coverage. Thus, the integration of mass drug administration should be strategically 
encouraged in resource-limited settings for the delivery of preventive chemotherapy to control 
soil-transmitted helminthiasis and other NTDs in Sub-Sahara African health facilities 
[32].Therefore, policy implementers should embark on integrated NTD control to have a big 
impact on diseases affecting the majority bottom poor [72]. 
 
1.2. Methods of Diagnosis of NTDS 
Methods available for detection of human helminths include wet mount or stained smear 
preparations, but the number of parasitic forms isolated by these two methods is often too low to 
be observed microscopically [88]. In most cases, the use of concentration techniques is preferred 
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as this increases the chances of detecting parasitic organisms, thus increasing the sensitivity of 
the microscopic techniques. The two most commonly used stool concentration techniques are 
Kato Katz sedimentation and flotation techniques [45]. Sedimentation techniques by Kato Katz 
are performed in general diagnostic laboratories because they are easier to perform and with few 
technical errors [93]. 
Unlike S. heamatobium infection, which is diagnosed by detecting eggs in urine [94], other soil 
dwelling helminthic infections are detected mainly from stool samples using the traditional ‘wet 
mount method’ for detection of helminths eggs. Other diagnostic methods can be used like 
concentration techniques using Kato Katz methods for qualitative detection of worm burden for 
schistosoma spps eggs and hookworm eggs [93,95,96]. It is also possible to detect eggs in stool 
using formal ether concentration techniques for the detection of eggs of Ascaris lumblicoides, 
trichuris trichiura and hookworm [97]. 
 
1.2.1. Kato Katz techniques for estimating worm burdens for STHs 
The Kato-Katz technique is a laboratory method for preparing human stool samples prior to 
searching for parasitic eggs [93]. Published methods vary in details however; one involves 
staining a sieved faecal sample and examining it under a microscope. The eggs of any soil-
transmitted helminths can be detected by experienced technician [98]. The total number of 
stained eggs are counted and used to calculate the number of eggs per gram (epg), also known as 
the worm burden, following known standard methods [96,99]. 
 
1.2.2. Formal ether concentration for identification of STHs 
In developing countries, the diagnosis of parasitic infections in humans is challenging and 
requires the recognition of parasite stages based on size, morphology, colour, and movement of 
parasitic organisms by trained and experienced individuals [100].The size and morphology are 
the major diagnostic microscopic features for their identification [100,101]. A formal ether 
concentration technique is one concentration procedure that should be performed as a routine 
part of a complete examination for parasites [28]. Such stool concentration allows the detection 
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of parasites present in small numbers. Otherwise, the diagnostic features of helminthic eggs or 
their larva may be missed by using direct wet mount methods [102]. 
 
1.2.3. Concentration techniques over traditional methods 
During concentration techniques, parasitic elements are concentrated through sedimentation to 
enhance the recovery of eggs in faecal specimens [102]. The concentration of eggs is possible 
because the specific gravity of helminthic eggs is greater than that of water [103]. In principle, 
formalin acts both as a fixative and preservative of helminthic eggs. During this process, faecal 
fragments are extracted into the ether phase so that the parasitic forms can be separated by 
centrifugation s [28]. The advantage of using this method over wet mount preparations is that of 
high sensitivity and specificity which makes it superior to wet methods [101] because more 
parasitic eggs can be identified using concentration techniques with microscopy and thus this 
method is superior to the wet mount preparations [100].   
 
1.3. Soil-Transmitted Helminths and Malaria 
Human helminth and malaria form the two of the most prevalent infections that overlap 
extensively in their geographical distribution and usually co-exist in the same host [104]. Current 
findings demonstrate that STH and malaria infections are prevalent and exhibit complex 
interactions within the host [75,104]. Soil transmitted helminths are the most prevalent infections 
among poor communities in most parts of Africa [15]. Importantly their co-existence with other 
infections such as HIV, TB and malaria make them amenable to population-wide interventions 
because control programs for HIV, TB and malaria are well developed and financed [105–107] 
and the addition of anthelminthic therapies to such programs would be simple. However, 
research on helminths remains poorly funded even during the era of ARV roll out programs in 
Africa [15]. In most countries in Africa¸ the funding opportunities for malaria, TB and 
HIV/AIDs control and prevention are highly prioritised whilst this is not the case for soil 
transmitted helminths and this is why the latter are categorised as neglected tropical diseases 
[106]. The same situation exists for lymphatic filariasis, onchocerciasis, schistosomiasis, and 
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trachoma [108]. However, from the treatment point of view, all these NTDs can be controlled by 
preventive chemotherapy using currently available cost effective drugs [109] 
Prospects of integrating control programs for malaria, HIV and TB with NTDs are reported in 
literature but are not widely applied in high endemic settings [62]. Therefore, if the control of 
these infections could be made community-based, there is a potential for integrated NTD and 
HIV/AIDs antiretroviral therapy programs to operate together with existing malaria control 
programs, thus utilizing the infrastructure used in the roll-out of freely provided ARTs in these 
settings [110,111]. The soil-transmitted helminths (STHs) are the central focus of the current 
study, and are each briefly described below.  
 
1.3.1. Ascaris lumbricoides 
Ascaris lumbricoides demonstrates cosmopolitan distribution [38,28].  Its highest prevalence is 
within tropical and subtropical regions, and is common in areas with inadequate sanitation such 
as refugee camps and congested communities but is highest in children of school going age and 
women of childbearing age [38]. Infection in humans is acquired through the ingestion of 
infective eggs from contaminated soil and food [38,112]. 
 
1.3.2.  Trichiuris trichiura 
The nematode (roundworm) Trichiuris trichiura, also called the ‘human whipworm’, causes 
trichuriasis in humans [113]. It is estimated that 800 million people are infected worldwide [114]  
Infection in humans is through ingestion of infective eggs from contaminated faecal materials; 
diagnosis is by identification of mature eggs from stools using microscopy, and infection can be 
treated by using albendazole, the major anthelminthic chemotherapy available [115,116]. 
 
1.3.3. Nectar americanus and Ancylostoma duodenale: Hookworm species 
The human hookworms include the nematode species, Ancylostoma duodenale and Necator 
americanus [117]. A larger group of hookworms infecting animals can also invade and parasitize 
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humans (A. ceylanicum) or can penetrate the human skin, causing cutaneous larva migrans [28], 
but the infection does not develop any further with A. braziliense  being an example of such an 
infection [118]. Occasionally A. caninum larvae may migrate to the human intestine, causing 
eosinophilia enteritis. Studies indicated that hookworms are the cause of the second most 
common human helminthic infection after ascariasis [40,117–121]. They are commonly 
distributed in areas with moist and warm climates widely in Africa, Asia and the Americas [121]. 
Although much improvement has been made in the diagnosis and prevention of soil transmitted 
helminths, many NTDs still remain severely under-treated because of lack of sufficient funding 
to address the disease burden [44]  International organizations, and academia, as well as public–
private partnerships (PPPs), have recently begun to focus more on NTD drug discovery 
[29,44,72,122]. Yet these efforts alone have been insufficient. Importantly, these diseases are 
often very dynamic and keep expanding in places where hygiene is poor [20]. This study, seeks 
to provide evidence to lend weight to one view in a controversy about effect of anthelminthic on 
disease markers of HIV progression in pregnant women on ART in a targeted versus untargeted 
cohort fashion. 
 
1.4. Research Gaps  
This section describes information from previous studies and the results of recent randomised 
control trials on the effect of deworming on HIV/AIDs immune progression markers. These 
studies have led to the identification of the main research questions, which I have attempted to 
answer in this PhD study. This section further describes programs against HIV/AIDS and 
initiatives to improve access to ART; mainly in rural and urban health facilities providing 
Antenatal care services. It provides different perspectives regarding the definition of co-infection 
by NTDs/helminths and HIV, reviewing studies on co–infection, including those among HIV-
infected pregnant women in African antenatal settings. After a brief review of the literature on 
the effects of helminths infection on HIV and malaria disease progression, the author lays out a 
problem statement, study aims, objectives, and hypothesis of the study, and its significance. 
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1.4.1. Problem statement and outcome measures 
The studies on the relationship between helminths and HIV/AIDS have been small in African 
antenatal settings (2, 83-85). The impact of malaria on anaemia and the important interplay with 
helminths demonstrate the need to address the interactions between HIV diseases, malaria and 
intestinal helminth infections in pregnant women. Earlier studies have not documented the 
beneficial effects of targeted versus non-targeted de-worming in pregnant women, and have not 
tested the hypothesis that de-worming may slow disease progression in HIV-infected patients on 
antiretroviral therapy with either or both of these two methods. The use of a non-targeted 
approach would be more pragmatic as it would not require testing for the presence of helminth 
infection and may therefore be more appropriate in resource-limited environments. Due to the 
roll out of ART in many African countries, a large number of pregnant females now receive 
ART. It is therefore important to study the effect of anthelminthic therapy in this group of 
subjects, for whom no data currently exists.   
This research study comprised of a pilot study to investigate the prevalence of, and the risk 
factors for, helminth and malaria co-infections in HIV-positive, pregnant females receiving ART. 
A second study sought to elucidate the benefits of de-worming HIV infected, ARV-treated 
pregnant females using two different de-worming approaches: targeted and non-targeted de-
worming. The examined outcomes were the impact on host viral load detection levels, CD4-cell 
counts, prevalence of helminths, malaria and serum haemoglobin levels. 
 
1.4.2. Purpose of the study 
The aims of this study were: to determine the prevalence and risk factors for helminth-malaria 
co-infections in pregnant HIV-positive females receiving ART; to investigate whether treatment 
of helminth infections in HIV infected pregnant women have any beneficial effect on HIV 
disease progression markers, such as viral load and CD4 cell counts; to determine the effects of 
de-worming on haemoglobin levels and body mass index; to determine the prevalence of malaria 
infections in the absence and presence of a helminth infection; to determine the efficacy of two 
de-worming intervention methods i.e. targeted and untargeted. It should be noted that the 
investigation of the effect of different ART regimens on the risk of helminth or malarial infection 
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was not an initial aim of this project, and therefore the study was not designed with this purpose 
in mind. However, following analysis of the data from the initial pilot study and the baseline data 
from the longitudinal study, it became clear that ART did have some effects, although 
inconsistent, on infection rates. These results therefore became quite prominent in the first two 
papers that were published from this PhD, and are therefore presented in the first two results 
chapters (chapter 3 and 4) of this thesis. 
 
1.4.3. Study objectives 
1. To determine the prevalence of helminthic-HIV co-infections among pregnant women in 
rural and peri-urban regions of Rwanda. 
2. To determine the prevalence of malaria infection in HIV-positive pregnant females with and 
without helminthic infection in rural and peri-urban regions of Rwanda. 
3. To determine the principal risk factors for helminth, P. falciparum and helminth-P. 
falciparum co-infections in HIV infected pregnant Rwandan females. 
 4. To determine the effect of anthelminthic therapy on HIV viral loads, CD4 cell counts and 
anaemia among pregnant women in the absence and presence of helminth co-infections in 
Rwanda. 
5. To determine the effect of anthelminthics on the incidence of helminthic infections in HIV-
positive pregnant Rwandan females in targeted and untargeted treatment arms over time. 
 
1.4.4. Hypotheses tested 
The hypotheses tested in this thesis were as follows:  
1. Helminth-malaria dual infections and helminth infection prevalence is higher among HIV 
infected pregnant women on ART in Rwanda in rural compared to urban health centres. 
2. Malaria–helminth co-infection and helminth infection risk negatively correlate with socio-
economic status of the HIV-infected pregnant women on ART in Rwanda. 
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3. Deworming has a positive effect on HIV/AIDS immune progression markers i.e. CD4 
counts, among HIV infected pregnant women on ART in Rwanda. 
4. De-worming using a targeted or a non-targeted approach is equally effective at reducing 
helminth infection levels. 
 
1.4.5. Significance of the study 
The results of this study have the potential to add weight to the national health policy related to 
the control and treatment of helminths and other NTD infections and malaria in HIV-positive 
pregnant females in Rwanda. The results sheds insight on the possible benefits of untargeted de-
worming (mass treatment) or targeted de-worming (diagnosis and subsequent treatment) of 
helminthic infections as part of routine HIV care in antenatal clinics across Rwanda. 
1.5. Summary 
The NTDs are a major source of morbidity and mortality in Africa. Furthermore, regions in 
which these diseases are prevalent also have high prevalence levels of malaria and HIV. These 
overlapping epidemics have severe effects in at risk populations, most particularly pregnant 
females. However, few studies have examined the interaction of these diseases in pregnant 
women in sub-Saharan Africa. The few randomized control trials of anti-helminthic therapy that 
have been conducted did not include HIV-infected women on ART and thus little data is 
available on the effect of de-worming on immune progression and anaemia in such cases. The 
current study will attempt to provide this data and to compare the effectiveness of a targeted anti-
helminthic drug intervention to a non-targeted format. 
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2. Chapter 2: Materials and Methods 
2.1 Introduction 
This chapter describes the procedures and methods applied to conduct the baseline helminth 
prevalence study and the prospective interventional study to determine the effect of deworming 
on immune markers of HIV-1 disease progression among HIV-infected pregnant women on 
ART.  
2.2 Description of pilot study and intervention study 
The first study was carried out as a pilot study to validate the study tools and generate 
information on the prevalence of helminth and malaria co-infection in pregnant females 
receiving ART. The pilot study was conducted at three conveniently sampled PMTCT sites in 
the Ruhuha, Mareba (both rural sites) and Biryogo (peri-urban) districts, which are mainly rural 
and peri-urban settings with ANC and ARV services for HIV-infected pregnant women on ART. 
This study also assessed the effect of ART on the prevalence of helminth and malaria infections 
in HIV-infected pregnant women. Findings from the pilot study were used in the design of the 
longitudinal cohort study. The results from the pilot study are described in Chapter 3 of this 
thesis.   
After obtaining data from the pilot study, we then enrolled pregnant female subjects receiving 
ART into a longitudinal cohort study based at the following health centres: Kamabuye, 
Rugarama, Kanombe, Masaka, Kicukiro, and Kacyiru. This study was split into 2 parts: a 
baseline study in which the prevalence of, and risk factors for, helminth and malaria infection 
were analysed. These data are described in Chapter 4. These same participants were then 
followed-up through pregnancy in an intervention study in which 2 different methods of 
deworming i.e. targeted and untargeted, were compared in terms of prevention of helminth 
infection and effects on malaria infection and CD4 counts and viral loads. Data from this study is 
provided in Chapter 5.     
The baseline and longitudinal studies were carried out from January 2010 to December 2010 by 
a study team of project-recruited nurses, midwives, laboratory technicians, clinical officers and 
site doctors. All members of the study team were trained to use the study tools (see Appendix 3 
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and 4: Follow up and case report forms). The pilot and longitudinal studies will be described in 
detail in the following sections of this chapter.  
2.2.1 Population and sample characteristics 
The populations in both studies [pilot and longitudinal] consisted of HIV-positive pregnant 
women attending antenatal services in their second trimester. The subjects in the initial pilot 
study were investigated only at one-time point whilst those in the longitudinal study were visited 
twice during their pregnancy at 3 monthly intervals, followed by 2 visits over six months in the 
post-partum period. All HIV-positive women in both studies were on anti-retroviral therapy 
(ART) as per national PMTCT service guidelines of the Rwandan Ministry of Health, which 
follow WHO recommendations for pregnant women receiving highly active anti-retroviral 
therapy (HAART) [126]. 
2.2.2 Intervention and sampling procedures   
Within the intervention study, in the ‘targeted treatment’ arm, participants who tested positive 
for helminths were treated with an anthelminthic (albendazole), while those found negative were 
not treated. In the ‘untargeted treatment’ arm, testing for worms was done and records captured 
at all visits, but all participants were de-wormed irrespective of whether or not they had a worm 
infection. 
2.2.3 Sample size estimation 
A sample size calculation was not performed for the pilot study (Chapter 3) with the sample 
number (328) used being based purely on logistical factors.  
For the intervention study we estimated that 100 pregnant females per treatment group (N=490 
per group) would be helminth infected, based on data from the pilot study. That would allow us 
to detect a difference in plasma viral load of 250 copies/mL. This assumes a power of 80% at a 
5% significance level. The total number of pregnant women enrolled into the study was therefore 
980 randomized into two groups of 490 each for the targeted deworming arm and the untargeted 
deworming arm. 
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2.2.3.1 Randomization 
Within the intervention study computer-assisted modelling was used to allocate each participant 
randomly to the targeted or untargeted treatment arms. For this purpose, at first enrolment into 
the study each participant was issued with an I.D. number, which was randomly drawn. Records 
were kept under lock and key by the Principal Investigator in Rwanda and a copy was provided 
to the project supervisors in Rwanda and South Africa. The intervention was not completely 
blinded, as participants may have been able to recognise which subjects were receiving the white 
tablet (albendazole) from the study nurse. The investigators were not blinded to assignments. 
2.2.4 Inclusion Criteria 
These criteria were used in both the pilot and the intervention studies. 
• HIV+ pregnant women in their second trimester 
• Attending antenatal services or PMTCT in the selected rural or peri-urban health 
centres 
• Aged 18-45 years  
• On highly active retroviral treatments (HAART) or prophylactic ART therapies 
• Ability to provide3 stool samples on three consecutive days for helminths assay 
2.2.5 Exclusion criteria 
These criteria were used in both the pilot and the intervention studies, except where noted. 
• HIV negative pregnant women 
• Below 18 years of age  
• In first trimester of pregnancy or reporting at antenatal clinic late in third trimester 
• Pregnant woman unable to stay within one health centre for more than six months 
after delivery (intervention study only) 
• At enrolment not willing to sign consent to the study  
2.2.6 Study visits and study data collection procedures 
The study sites for the intervention study were 6 health care centres: Kamabuye, Rugarama 
Kanombe, Masaka, Kicukiro, and Kacyiru. These sites did not include the 3 health centres that 
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were used in the pilot study i,e, Mareba, Ruhuha, and Biryogo, and were strategically selected 
from a list of health facilities that have PMTCT/ANC/ART services and were near to lakeside 
areas where helminth prevalence is expected to be high among women of reproductive age.   
During the intervention study participants had two antenatal visits and two post-partum visits to 
each participating health centre. During each visit, sampling for helminths, haemoglobin levels, 
CD4 counts and viral loads and malaria tests were performed. The study midwife also measured 
body mass index at each visit.  
1. At visit 1 (V1) (baseline visit), women were screened for inclusion criteria and asked to sign 
consent forms. Upon enrolment in the study, each woman was given a study ID number and 
was physically examined by the study site doctor or a protocol- trained nurse or midwife who 
collected the required physical data, including age, trimester of pregnancy and medications 
being used by the study subjects.  
2. More individual data were collected using the questionnaire forms (Appendix 3) that 
included the type of ART and its duration, use of supplements, TB history and results; anti-
helminthic treatment history and helminth-related risk factors were also obtained in this way. 
3. Laboratory specimens collected included stools for helminth testing, blood for haemoglobin, 
and blood slides for malaria parasites and histidine-rich protein assessments. More blood was 
collected according to the study protocols by PMTCT/ANC laboratory staff for CD4 cell 
count and viral load assays. At each visit, three stool samples were analysed for helminth-
intensity determination using Kato–Katz test [128]. 
4. At visit 2 (V2) most women had reached their third trimester. A doctor, nurse or midwife 
determined the gestation stage.  
With the exception of the viral load assay test (done only at V1 and V4), all other samples were 
collected on visits 1, 2, 3 and 4 of the study period. After delivery, the women’s data were 
collected as described in Figure 1 of Appendix 1.  
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Table 2.1. Investigational schedule 
 
No VISITS  PARTICIPANTS 
TIME BETWEEN 
VISITS 
TESTS/VARIABLES   
1 
Visit 1 
Baseline 
Pregnant woman 3 months  Hb,CD4,vl,BS,hrp-2,epg, BMI 
2 Visit 2 Pregnant woman 3 months  Hb,CD4,BS,hrp-2,epg, BMI 
3  Visit 3 Mother  3 months  
Hb,CD4, BS,hrp-2, 
epg, BMI 
4  Visit 4 Mother 3 months  
Hb,CD4, VL, BS,hrp-2 
epg, BMI 
 
KEY: Hb = haemoglobin level, epg = eggs per gram faeces, BS = blood slide for malaria HRP-2 = histidine rich 
protein-2 antigen, CD4 = cluster of differentiation-4, VL = viral load, BMI = body mass index 
 
 
2.2.7 Sample collection 
In the intervention study for the purpose of sample collection during the interviews at all 4 study 
visits participating women were supplied with labelled plastic containers, waterproof papers and 
applicator sticks, and were instructed to bring stool samples three times on different days to the 
health centre laboratory project technician for testing. Blood was also drawn from subjects for 
immunity markers before and after the intervention period in both study arms. These samples 
were taken twice during antenatal visits and twice on post-partum visits to the health centre. 
Samples were sent to the National Reference Laboratory in Kigali for viral load assays. A case 
report form (CRF) was administered in the form of a structured questionnaire to all participants 
(Appendix 4). Information captured included personal hygiene behaviour, age, height, weight, 
parity, gestational stage, level of education and HIV/AIDS treatment services received at 
antenatal care units, including any TB clinical history and presence or absence of any nutritional 
E. Ivan PhD thesis  Page 22 
 
supplements. The women were interviewed in their mother tongue, Kinyarwanda, and translated 
into English for data transcription forms. 
2.2.8 Physical examination of the participants 
Participants’ social demographic data were collected using the case report form (CRF) described 
in Appendix 4 administered in form of a questionnaire. Physical data captured on the CRF were 
also entered into an Access or Excel spread sheet to enable cleaning of data before analysis.  
Anthropometric indices were determined, with weight taken to the nearest 0.5 kg, using a 
calibrated measuring scale, height measured in meters, and body mass index calculated there-
from. Body mass index (BMI) was computed as weight (kg) divided by height (m) squared, as 
described [129]. 
2.2.9 Intervention assignments 
Study arm A. 
• These subjects were given anthelminthic if they tested positive for helminth infection 
at any of the 4 study visits.  
• In this targeted arm, women who tested helminth-negative did not receive 
anthelminthic. 
Study arm B. 
• This consisted of a non-targeted intervention arm; all participants in this arm received 
anthelminthic, irrespective of helminth-infection status, at all 4 study visits. 
Treatment to subjects in both arms 
• All helminth-positive women in arm A and all women in arm B received a single 
dose of albendazole (400mg) at all 4 study visits.  
• In both arms women who had malaria were treated with anti-malarial therapy in the 
form of Coartem® (120mg artemether -20mg lumefantrine) at each study visits at 
which they tested positive for P. falciparum 
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• Iron supplements were given in accordance with the Rwanda Ministry of Health 
guidelines for antenatal women i.e. an iron supplement was given to all pregnant 
women with a haemoglobin concentration of < 8g/dl [127].  
It is known that ART reduces viral replication and can reduce mother-to-child transmission of 
HIV by lowering plasma viral load in pregnant women and in their new-borns [130]. In this 
study all women enrolled were given highly active antiretroviral treatment (HAART) in 
accordance with the Rwandan Ministry of Health guidelines [127]. These guidelines state that 
pregnant mothers should be initiated on HAART irrespective of CD4 cell count levels [126]. The 
following regimens are available in Rwanda [126,131]: 
First line treatment: AZT (Zidovudine) +3TC (Lamivudine) + Nevirapine (NVP). In case of any 
complications AZT is replaced with d4T (stavudine) [127] 
Second line treatment: Abacavir (ABC), +Tenofovir (TDF) + Lopinavir (LOPV/r) [127]  
2.2.10 Follow-up procedures 
A six-month post-partum period was used to record any significant changes in mothers for each 
of the de-wormed and non-de-wormed arms. At each visit, information about the occurrence of 
symptoms, dropouts, illness and treatment, were recorded in the investigators’ notes and 
captured on a study progress form, which was updated during each visit. Home visits by four 
members of the study team drawn from the list of local collaborators in Rwanda were arranged to 
follow up women that dropped out of the study. A database of participants’ addresses was 
developed and used to trace them to their homes by mobile phone contact and site visit where 
possible, with help of community health workers. 
2.2.11 Unexpected or unusual symptoms and possible risks of the study 
Any adverse reaction or unusual symptom of any nature or severity which was not consistent 
with the study investigational protocol and not in agreement with the International Clinical 
Harmonization (ICH) Guidelines for Clinical Safety Data Management was treated by the study 
doctor in collaboration with clinical coordinators. The principal investigator regularly reported to 
the Institutional Review Board (IRB) in Rwanda while adhering to the existing research 
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principles of the Rwandan Ministry of Health treatment guidelines to safeguard the study 
subjects according to the principles of the Helsinki Declaration [132]. 
Risks There were minimal risks to subjects participating in this study. The only risk in taking 
part in the study could have been mild and short-lived drug reactions that could be easily treated 
by the research team doctor.  
Potential side effects of medications used 
Albendazole 
Albendazole therapy during pregnancy is not associated with a significant increase in major 
congenital defects [133,134] but it should be avoided during the first trimester. The therapy 
offers beneficial effects to pregnant women in countries where intestinal helminths are endemic 
[135,136].  
Iron supplements 
There is evidence that supplementation with iron can be provided safely with anthelminthic 
treatment [137]. Current practice in Rwanda recommends giving an iron supplement to all 
pregnant mothers for anaemia if the haemoglobin concentration is < 8g/dl in second trimester, 
and this was applied in the current study. There were minimal side effects of iron 
supplementation to pregnant mothers, and the research team doctor treated any effect noted 
during the study. 
Coartem® (artemether 120 mg plus lumefantrine 20 mg) 
In the case of pregnant women who tested positive for malaria, Coartem was given in four doses 
over three days, i.e. two doses on day 1 and one dose each on day 2 and 3 [138]. Side effects of 
Coartem treatment in pregnant women is rare and minimal [139], consisting of nausea, vomiting 
and neurological disorders, and whenever any of these side effects appeared, the study doctor 
treated the participants. 
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AZT and NVP as first-line ART treatment 
Side effects like diarrhoea and anaemia are related to AZT therapy and an NVP-related rash may 
also be encountered, and where they arose, the participants were treated by the study doctor 
according to guidelines of Rwandan Ministry of Health. Neonates may experience lower birth 
weight or congenital effects like neurological disorders. All these are rare side effects of the ART 
treatment regimen to mothers, and were treated by the study team doctors in accordance with 
Rwanda Ministry of Health guidelines for all subjects in the study [131]  
2.3 Laboratory analyses 
2.3.1 Laboratory stool analysis 
Three slides were prepared for each stool sample collected on three different days from each 
participant and processed at each visit to the clinic by the Kato-Katz method as described 
previously [140]. Using standard methods three Kato-Katz slides were prepared from each of 
three stool samples collected on consecutive days, and examined within 30 minutes for 
Ancylostoma duodenale and Necator americanus and again the following day for the ova of 
Ascaris lumbricoides and Trichiura trichiura [140,141]. Eggs per gram (EPG) of stool were 
calculated by taking the mean of the mean values obtained for each of the three stool samples. 
Prevalence and incident rates as new events were measured by using methods previously 
described [142]. Sensitivity and specificity of different stool concentration methods were 
considered using standard laboratory methods [143].  
The study utilized use of Kato Katz multiple stool slides taken at three consecutive days and 
compared the results with that of formal ether concentration technique for ensuring high 
sensitivity and specificity to identify helminths [143]. This rigorous approach has been 
recommended to yield high sensitivity and specificity for helminths prevalence [140,141]. 
2.3.2 CD4 and plasma viral load analysis 
The CD4 cell counts were determined at enrolment using Multiset® software on a FACS Calibur 
XT1800i® dual-platform system (Becton Dickinson BD, San Jose, CA, USA). Plasma HIV 
RNA was quantified using a Gen-probe® HIV-1 viral load assay on a AmpliPrep/Cobas 
Taqman® (HIMCAP, Fort Lauderdale, FL, USA) [144]. 
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2.3.3 Haemoglobin measurement 
A blood drop was obtained using a finger prick device and tested for haemoglobin using a 
DOTmed ®, Hemocue®device [145,146]. A haemoglobin level of less than 8g/dl was defined as 
anaemia.  
2.3.4 Malaria assessment 
Asymptomatic parasitaemia was determined in all women participating in the study. Plasmodium 
falciparum was identified by light microscopic examination of Giemsa-stained thick and thin 
blood smears. Study participants were also tested with an HRP-2 rapid immunochromatographic 
dipstick test (Paracheck-F®, IndMED, India) for malaria antigen positivity rates [147]. This test 
can be applied easily in the field in epidemiological studies because it is a rapid kit method and is 
considered user-friendly [148-150].  
2.3.5 Quality control 
Quality control procedures involved review of laboratory slide results by trained experts from the 
National Reference Laboratory in Rwanda using existing standard operating procedures where 
10% of the examined stool specimen slides for helminths diagnosis, and malaria smears were re-
examined for concordance testing. Similarly, blood samples for CD4 and viral load assays were 
rechecked per standard operating procedures. All smears and samples were stored for review if 
required. In addition, a daily check of the quality of smears and samples were carried out by 
routine checks of study records by the principal investigator in accordance with Good Laboratory 
Practice (GLP) recommendations in Rwanda. 
 
2.4 Ethical considerations 
2.4.1 Ethics committees 
The protocol was submitted to the Rwandan National Ethics Committee through the Kigali 
Health Institute and the University of the Witwatersrand’s Ethics Committee, and the protocol 
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was approved by both organizations (see Appendix 1and 2 for Ethics Committee approval 
letters).  
2.4.2 Conduct of study 
The principal investigator of the research gave the invited participants a brief explanation of the 
study aims and objectives including study significance. All study participants were assured of 
confidentiality. Enrolment in the study adhered to the norms and declarations of Helsinki and all 
current amendments[132]. Procedures for the handling of study materials, collection of data and 
reporting of results were designed to maintain subject confidentiality and used study-coding 
arrangements within the requirements of good clinical practice and the Helsinki Declaration 
[151]. 
2.4.3 Information sheet and signing of consent 
All information that was obtained from the participants in the study remained confidential and 
was recorded under an ID number specific to each participant. Paper copies of our documents 
were kept secure in Rwanda; the database was password-protected in a computer with the 
supervisor at the Kigali Health Institute in Rwanda and sent to Professor Nigel Crowther at the 
University of the Witwatersrand in Johannesburg, South Africa, when deemed relevant for 
scrutiny and at subsequent analysis stages.  
2.5 Data Management and Analysis 
2.5.1 Data analysis 
All statistical analyses are described within the Methods section of each Results chapter. 
2.5.2 Data safety and monitoring (DSM) 
A local Data Safety and Monitoring (DSM) team worked with the principal investigator and 
included specialists with relevant skills in the fields of HIV/AIDS, parasitology, gynaecology, 
paediatrics, epidemiology and ethics. These people were drawn from a list of local collaborators. 
The monitors gave a written monitoring report to the sponsors at the Kigali Health Institute 
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Ethics Committee after each on-site data sheet appraisal and/or other study-related 
communication. 
2.5.3 Direct access to data 
The Permission to examine and reproduce any records and reports that are important to the 
evaluation of the study were given to the appropriate monitors by the principal investigator and 
the study supervisors. Any existing authorities, sponsor's monitors and auditors seeking direct 
access to data took all reasonable precautions within the constraints of the requirements of the 
study to maintain the confidentiality of the subjects' identities and investigator’s information.  
2.5.4 Data source documentation 
All variables were encoded in compliance with STATA.11 (Chicago, IL, USA) software, which 
was used for the initial analysis of all data. Further analyses were done using Statistica version 
9.1 (Stat Soft, Tulsa, OK, USA). The data from the laboratory, patient questionnaires, patients’ 
files and physical examination of patients were first entered into Excel spreadsheets and 
Microsoft Access using double-entry before being entered into STATA for analysis by the 
investigator and the statistician.  
Computer generated participant’s codes were double-checked by the principal investigator and 
study supervisors to ensure that they correspond with the source data from the field.  
2.5.5 Data collection 
Trainees from the Kigali Health Institute and the National Reference Laboratory (NRL) carried 
out the laboratory analyses while TRAC-plus and other independent clinical collaborators 
involved in the study assisted in monitoring the project activities. The PI was in charge of all the 
project activities and supervised these together with clinical collaborators, overseeing all data 
collection and laboratory tests. The PI also carried out the data entry, data analysis and reporting 
of the study activities. However, co-investigators with appropriate medical qualifications assisted 
the PI in overseeing medical issues of study subjects throughout the data collection period.  
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2.6 Dissemination of findings 
All study findings have been published and presented locally to the Rwanda Ministry of Health 
and to health centre authorities in Rwanda. Results were also presented as posters and abstracts 
at different conferences and manuscripts were published in international peer-reviewed journals 
as described in appendix 4 and 5 and 6 at the end of the thesis.  
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Chapter 3: Malaria and helminthic co-infection among HIV-positive 
pregnant women: prevalence and effects of antiretroviral therapy 
3.1 Abstract 
Introduction: The impact of malaria on anemia and the interplay with helminthes underline the 
importance of addressing the interactions between HIV/AIDS, malaria and intestinal helminthes 
infections in pregnancy. The aim of this study was to determine the prevalence of malaria–
helminthes dual infections among HIV positive pregnant mothers after 12 months on ART.  
Method: a cross sectional study was conducted on intestinal helminthes and malaria dual 
infections among HIV-positive pregnant women attending antenatal health centers in Rwanda. 
This was the pilot prevalence data carried out to validate study tools, before the main 
longitudinal study   
Results: stool and malaria blood slide examinations were performed on 328 women residing in 
rural (n = 166) and peri-urban locations (n = 162). BMI, CD4 cell count, hemoglobin levels, type 
of ART and viral load of participants were assessed. Within the study group, 38% of individuals’ 
harbored helminthes, 21% had malaria and 10% were infected with both. The most prevalent 
helminthes species were Ascaris lumbricoides (20.7%), followed by Trichuris trichiura (9.2%), 
and Ancylostoma duodenale and Necator americanus (1.2%). Helminthes infections were 
characterized by low hemoglobin and CD4 counts. Subjects treated with a d4T, 3TC, NVP 
regimen had a reduced risk of T. trichiura infection (OR, 0.27; 95% CIs, 0.10–0.76; p < 0.05) 
and malaria–helminthes dual infection (OR, 0.29; 95% CI, 0.11–0.75; p < 0.05) compared to 
those receiving AZT, 3TC, NVP.  
Conclusion: This study shows a high prevalence of malaria and helminth co-infection among 
HIV-positive pregnant women in Rwanda. The differential effect of ARTs on the risk of 
helminth infection is of interest and should be further examined in a double-blinded placebo 
randomized controlled trial in a larger patient group and explore the role of drug-drug 
interactions. 
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3.2 Introduction 
To summarize what has been said in earlier chapters, helminth and malaria infections have been 
hypothesized to be factors likely to be driving the HIV-1 epidemic in Africa (1,2). Globally, 
there are more than 2 billion people that are estimated to be infested with soil-transmitted 
helminths, with the geographical distribution of these infections overlapping considerably with 
regions of high HIV-1 sero-prevalence (1) and malaria endemicity (3,4). Due to their profound 
effect on the host immune system, which makes those infected more susceptible to HIV-1 
infection (1,5), malaria and helminth infections play an important role in the pathogenesis of 
HIV-1 infection in Africa.  
The combination of HIV, helminthic and plasmodial infections in a host create an 
immunologically complex profile (6) and substantially increase the risk of anemia, which is 
caused by all three types of infections (7). Therefore, in terms of co-infection with these diseases, 
pregnant women in sub-Saharan Africa represent a highly vulnerable group, particularly in light 
of data showing that helminth infection increases the risk of mother-to-child transmission of HIV 
(6). 
Recent data on the prevalence of helminth infection in Rwanda for school-going children from 
eight districts indicated a prevalence of 64.5%. The observed prevalence was higher in rural than 
in urban settings (8). However, no studies have documented the prevalence of malaria and 
intestinal helminth dual infections among pregnant women with HIV/AIDS attending antenatal 
services in the context of ARV roll-out programs. Therefore, the aim of this study was to 
determine the baseline prevalence of helminth and malaria dual infections in HIV-1 infected 
pregnant women attending Rwandan health centres after ART initiation. To give some context to 
the results given here, a brief description is provided of the methods used to obtain them. 
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3.3  Methods  
3.3.1 Study area and population 
Enrolled participants were a sample of women attending the antenatal health centre clinics in the 
provinces of Ruhuha, Mareba (both rural sites) and Biryogo (peri-urban) in Rwanda. These 
regions are within easy reach of Kigali, where all stool and blood samples analyses were to be 
performed. Health facilities were chosen based on facilities that had functional 
PMTCT/ANC/ARV services and were located near to inland lakes, thus increasing the chance of 
helminth infection. One such facility was chosen randomly from each of the 3 provinces. After 
having given their informed consent in writing, the selected women in the second and third 
trimester of pregnancy were enrolled. Women were excluded if they were HIV negative, below 
18 years of age, had clinical evidence of TB, and had a treatment history of anthelmintic therapy 
and clinical confirmation of an abnormal pregnancy. Upon enrolment, subjects were interviewed 
for demographic information, and the type and duration of the ARV treatment they were 
receiving.  
After informed consent was obtained, blood samples were collected for malaria microscopy, 
rapid malaria testing, haemoglobin level and CD4 cell count determination and viral load assays. 
Stool samples were obtained on three consecutive days for determination of helminthic infection. 
3.3.2 Other procedures 
Stool sample collection and examination from each woman involved fresh stool samples 
collected using an appropriate container, kept according to the national laboratory standards and 
then examined using microscopy by a lab technician trained for this procedure. Blood samples 
for malaria, viral load and CD4 samples were collected and analysed using available standard 
methods. The other methods used in this section of the thesis (described in detail in Chapter 2) 
are as follows: formal ether concentration methods for intestinal helminths identification in 
stools, identification of P. falciparum infection, measurement of serum haemoglobin levels, 
assessment of CD4 counts, viral load measurement (see page 25) and treatment of HIV 
infections (see page 23). Also described in Chapter 2 are the selection of the study sites and the 
sample size estimation (see pages 17-18) and inclusion and exclusion criteria (see page 19). 
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3.3.3 Statistical analysis 
Analyses were performed using Stata® version 11.0 (College Station, TX, USA) and Statistica® 
version 9.1 (Stat Soft, Tulsa, OK, USA). Data included in tables and the text of this chapter are 
expressed as mean ± SD or median (range from 25th to 75th quartile). Data that were not normally 
distributed were log transformed to normality. Comparison of continuous data between 2 groups 
was carried out using the Student’s non-paired T test, whilst data comparison across more than 2 
groups were performed using ANOVA with paired means analysed using Turkey’s test. A 
comparison of mean values between groups, with adjustment for possible confounding variables, 
was accomplished with the use of ANCOVA. Percentage levels were compared across study 
groups using the χ2 test. Backward, stepwise multiple regression analyses were performed to 
identify the principal determinants of haemoglobin levels and CD4 counts. Independent variables 
that were included in the initial regression model were those that correlated with the dependent 
variable with a significance level of p<0.10 in a Pearson univariate analysis. Variables were then 
removed one at a time based on their p-value, with the variable with the weakest p-value being 
removed in each round until only variables with p<0.05 were left in the model. Logistic 
regression was performed to assess the risk of infection across antiretroviral therapy (ART) 
regimens and data expressed as an odds ratio (OR) with 95% confidence intervals (95% CI). The 
categorical variable was infection/no infection whilst the independent variables were the ART 
regimens for which dummy variables were generated. The AZT-3TC-NVP regimen was set as 
the reference, with an odds ratio of 1. The logistic regression models were run with and without 
the confounding variable of location, i.e. peri-urban and rural, which were coded as 0 and 1 
respectively. 
 
3.4 Results 
3.4.1 Participants’ characteristics 
The study cohort of 328 pregnant women included 166 from rural and 162 from peri-urban 
centres. The median [range] age of the cohort was 27.0 [8.00] years, with no significant 
difference between the 2 population groups. The mean BMI (± SD) of the total cohort was 25.4 ± 
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3.44, with women from the peri-urban group (26.7 ± 2.88) being significantly heavier than the 
rural population (24.1 ± 3.46; p<0.0001).  
Participants were recruited to the study in the second and third trimesters of pregnancy, with 288 
(87.8%) women recruited in the second and 40 (12.2%) in the third trimester. No significant 
differences were noted between these 2 groups for any of the study variables, except that 53.5% 
of women recruited in their second trimester of pregnancy originated in a rural area, compared to 
30.0% recruited in their third trimester (p=0.005). 
3.4.2 Prevalence of helminth and malaria infections 
Table 3.1. Prevalence of malaria and helminth infections in rural, peri-urban and 
combined populations 
 
VARIABLES RURAL PERI-URBAN COMBINED 
N  (number of respondents) 166 162 328 
Malaria with or without helminth (%) 29.5 12.3*** 21.0 
Helminth with or without malaria (%) 
Specific species : Ascaris lumbricoides (%) 
                             Trichiura trichiura (%) 
                             Hookworm (%) 
                             Asc + Trich + Hkw (%)  
44.6 
23.5 
12.7 
1.81 
6.63 
32.7* 
17.9 
5.56* 
0.62 
8.64 
37.8 
20.7 
9.15 
1.22 
7.62 
Both malaria and helminths (%) 15.1 4.94** 10.1 
Eggs per gram of stool (EPG) 6236±6831 6491±4814 6342±6051 
 
Data given as % except for EPG (mean±SD); mean EPG was calculated using values only from subjects with a 
worm infection (N=74 for rural and 53 for peri-urban); *p<0.05, **p<0.005, ***p<0.0005 versus rural group. Asc= 
Ascaris lumbricoides, Trich = Trichiuris trichiura, Hkw = hookworm 
 
Table 3.1 shows that the prevalence of malarial infection with or without helminths (p<0.0005) 
(i.e. those cases with a malarial infection which did or did not include a helminth co-infection, in 
other words all cases with malaria) and of malarial-helminths dual infection (p<0.005) was 
significantly higher in the rural than in the peri-urban population. Helminth infections with or 
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without malaria (i.e. those cases with a helminth infection which did or did not include a malaria 
co-infection, in other words all cases with helminth infection) were also higher in the rural 
population (p<0.05), as was the prevalence of Trichuris trichiura infection (p<0.05). Cases were 
also detected where helminths infection was present without malaria. The prevalence of these 
‘helminths only’ cases was 27.7% in the rural population and 27.8% in the peri-urban group. 
Also, malaria was detected in subjects without a helminths co-infection. The prevalence of these 
‘malaria only’ cases was 14.5% in the rural population and 7.4% in the peri-urban group (p<0.05 
versus rural) with an overall prevalence of 11.0% in the combined population. The EPG values 
did not differ between the two groups. 
 
Table 3.2. Effects of helminth and malarial infections 
 
VARIABLES 
NO 
INFECTIONS 
MALARIA 
ONLY 
HELMINTHS 
ONLY 
BOTH 
MALARIA & 
HELMINTHS 
Number of subjects 168 36 91 33 
Age (years) 27.0 [7.00] 27.5 [9.50] 26.0 [9.00] 28.0 [9.00] 
BMI 25.7 ± 3.53* 25.5 ± 3.74 25.6 ± 3.03* 23.5 ± 3.31 
Haemoglobin (g/dl) 12.3 ± 1.10** † 12.1 ± 0.95 11.9 ± 1.17 11.5 ± 1.05 
Prevalence of anaemia 
(haemoglobin<12g/dl) (%) 
34.5** † 44.4 47.2 63.6 
CD4 (cells/mm3) 532 [181]** ††† 533 [203]* ††† 449 [131] 464 [156] 
 
Data expressed as mean ± SD, median [interquartile range] or percentage; *p<0.05, **p<0.005 versus 
both malaria and helminth; †p<0.05, †††p<0.0005 versus helminth only 
 
Table 3.2 shows that dual infection with malaria and helminths is associated with a lower BMI 
than in both non-infected (p<0.05) and helminth-only infected (p<0.05) subjects. Furthermore, 
compared to subjects with no infections, those with a malaria-helminth dual infection or an 
infection with helminths only are characterized by lower haemoglobin levels (p<0.005 and 
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p<0.05, respectively) and a higher prevalence of haemoglobin levels <12g/dL (p<0.005 and 
p<0.05, respectively). Subjects with malaria alone also had lower haemoglobin levels and a 
higher prevalence of reduced haemoglobin concentrations when compared to females with no 
infections; however, these differences were not statistically significant. Also, subjects with a dual 
infection or with a helminth-only infection had lower CD4 counts than subjects with no infection 
(p<0.005 and p<0.0005, respectively) and subjects with a malaria-only infection (p<0.05 and 
p<0.0005, respectively).  
Backward, stepwise multiple regression models were developed to identify the principal 
determinants of haemoglobin levels and CD4 counts. The initial regression model for 
haemoglobin levels included the following continuous variables: helminthic egg count and body 
weight, and the following coded (0 or 1) variables: helminthic infection, rural/peri-urban and 
detectable viral load. The final model retained only 2 variables that significantly correlated with 
haemoglobin level: helminthic infection (beta = -0.21, p<0.0005) and body weight (beta = 0.13, 
p<0.05). The R-value for the final regression model was 0.27 (p<0.0001). The initial regression 
model for CD4 counts included one continuous variable (helminth egg count) and the following 
coded variables: helminthic infection, rural/peri-urban and antiretroviral treatment regimen. The 
final model retained only 1 variable that significantly correlated with haemoglobin level: 
helminthic infection (beta and R = -0.35, p<0.0001).  
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3.4.3 Anti-retroviral treatment regimens and their effects 
Table 3.3. Comparison of anti-retroviral regimens used in rural and peri-urban 
populations 
 
ANTI-RETROVIRAL REGIMENS RURAL PERI-URBAN 
d4T-3TC-NVP (%)  63.2 0.00*** 
AZT-3TC-NVP (%) 19.9 3.09*** 
AZT-NVP (%) 0.60 95.1*** 
AZT (%) 12.0 1.23*** 
Other (%) 4.22 0.62* 
 
*p<0.05, ***p<0.0005 versus rural group 
  
Table 3.3 shows that there were significant differences in the antiretroviral regimens that were 
used at rural and peri-urban sites. Thus, over 95% of peri-urban centres used the AZT-NVP 
regimen. The most common (63.2%) regimen in use at rural sites was the d4T-3TC-NVP triple-
combination. 
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Table 3.4. Comparison of BMI, haemoglobin and CD4 levels and prevalence of detectable 
viral load and helminthic and malaria infections across ARV treatment groups 
 
Variables d4T-3TC-
NVP 
AZT-3TC-
NVP 
AZT-NVP AZT 
N  105 38 155 22 
Duration of ARV therapy (months) 8.62 ± 14.2 6.52 ± 9.64 8.76 ± 14.5 9.37 ± 14.9 
BMI 24.3 ± 
3.56*** 
24.0 ± 
3.22*** 
26.9 ± 2.8 22.9 ± 
2.25*** 
Hemoglobin (g/dl) 12.0 ± 0.87 12.1 ± 1.29 12.2 ± 1.21 12.0 ± 1.25 
CD4 (cells/mm3) 490 [111] 463 [223] 500 [201] 537 [328] 
Detectable viral load (%) 0.95† 10.5 0.00††† 0.00 
Eggs per gram stool (EPG) 4292 ± 
4881* 
7344 ± 6409 7060 ± 6336 6371 ± 4902 
Helminth with or without malaria 
(%)              Specific species:  
Ascarislumbricoides (%) 
Trichiuris trichiura (%) 
Hookworm species (%) 
Asc + Trich + Hkw (%) 
40.0† 
 
22.9 
8.57† 
0.00 
8.57 
65.8 
 
26.3 
26.3 
5.26 
7.89 
32.2†† 
 
19.3 
4.52††† 
0.64 
7.74 
31.8† 
 
13.6 
13.6 
0.00 
4.54 
Malaria with or without helminth 
(%) 
25.7* 39.5*** 12.3 27.3 
Both helminth and malaria (%) 12.4* 23.7** 5.16 9.09 
 
Data expressed as mean ± SD or median (interquartile range) or percentage; mean EPG was calculated 
using values only from subjects with a worm infection (N=42 for d4T-3TC-NVP, 25 for AZT-3TC-NVP, 
50 for AZT-NVP and 7 for AZT); *p<0.05, **p<0.005, ***p<0.0005 versus AZT-NVP;†p<0.05, 
††p<0.005, †††p<0.0005 versus AZT-3TC-NVP; Asc = Ascaris lumbricoides, Trich = 
Trichiuristrichiura, Hkw = hookworm 
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Table 3.4 shows that duration of ARV therapy, haemoglobin levels and CD4 counts were not 
significantly different across the four treatment groups. However, BMI was significantly higher 
in those receiving AZT and NVP when compared to all other groups (p<0.0005 for all 
comparisons). Also, the prevalence of a detectable viral load (DVL) was higher in the AZT-3TC-
NVP treatment group compared to both the d4T-3TC-NVP (p<0.05) and the AZT-NVP groups 
(p<0.0005). This pattern was reproduced in the prevalence of helminths with or without malaria 
(p<0.05 and p<0.005, respectively) and Trichiura trichiura infections (p<0.05 and p<0.0005, 
respectively). It was also observed that malaria with or without helminths infections was more 
common in the d4T-3TC-NVP and AZT-3TC-NVP treatment groups compared to the AZT-NVP 
group (p<0.05 and p<0.0005, respectively). The same pattern was also observed for helminthic-
malaria dual infections (p<0.05 and p<0.005, respectively). The EPG value for the d4T-3TC-
NVP group was significantly lower than in the AZT-NVP group (p<0.05), and also lower than in 
the AZT-3TC-NVP group, but this difference did not reach statistical significance (p=0.08).     
Only 6 subjects (1.83%) had a DVL (>40 RNA copies/mL) and the median CD4 count in these 
subjects was significantly lower than in those with an undetectable viral load (UVL; 363 [114] 
versus 493 [173] cells/mm3; p<0.0001). All the participants with a DVL tested positive for 
helminthic infection, whereas only 36.6% (p<0.005) of subjects with an undetectable viral load 
(UVL) were infected with helminths. Malaria was also more common in subjects with a DVL 
(50.0% versus 20.5%; p=0.08) but this difference did not reach statistical significance. The 
prevalence of helminthic co-infection with malaria was also more common in those with a DVL 
(50.0% versus 9.32%; p<0.005). Haemoglobin levels were lower in subjects with a DVL 
compared to those with an UVL (11.0 versus 12.1 g/dl; p<0.05). However, after adjusting for the 
presence of a helminths infection using ANCOVA, the p value was attenuated (p=0.08).  
The data in Table 3.4 suggest differential effects of the ARTs on malaria and helminths 
infections. This was investigated further by logistic regression analysis in which the odds ratios 
for risk of infection for each ARV treatment regimen was calculated with and without adjustment 
for location (peri-urban/rural), which was the only possible confounding variable. The AZT-
3TC-NVP regimen was set as the reference with an odds ratio of 1. The results of this analysis 
are shown in Table 3.4. The data demonstrate that the d4T, 3TC, NVP regimen reduces the risk 
of Trichiura trichiura infection and the risk of a combined malaria and helminths infection when 
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compared to the AZT-3TC-NVP regimen, and that adjustment for location does not cancel out 
this effect. This was also observed for the effect of AZT-NVP on the risk of Trichiura trichiura 
infection.  However, adjusting for location did attenuate the significant risk reduction observed 
for this ARV regimen on both malaria and dual malaria-helminth infection. It was also observed 
that for the d4T-3TC-NVP regimen, after adjustment for location, the odds ratio for malaria was 
slightly attenuated, with this effect just missing statistical significance (p=0.06). 
 
3.5 Discussion 
The current study shows that helminths and malaria infection levels in HIV-positive pregnant 
women are high, and that malaria and malaria-helminths dual infections are more common in 
rural than in urban areas. Malaria-helminths dual infection was found to be a risk factor for 
reduced BMI, whilst helminths infection either on its own or in conjunction with malaria was 
found to be associated with lower haemoglobin and CD4 levels. The ARV regimen of d4T-3TC-
NVP was found to significantly reduce the risk of Trichiuris trichiura and malaria-helminthic 
dual infection when compared to the AZT-3TC-NVP regimen, whilst AZT with NVP also 
lowered the risk of Trichiuris trichiura infection.  
A prevalence rate of 37.8% for helminth infections and 21.0% for malaria indicates a high 
transmission intensity of these parasites among HIV-positive pregnant women in Rwanda. An 
earlier study of malaria prevalence conducted among HIV-positive pregnant females in Kigali, 
Rwanda, demonstrated that 8.0% of the study group had malaria [166]. This figure is comparable 
to the prevalence (12.3%) of malaria observed in our study for subjects residing in the peri-urban 
areas of Kigali. No studies have been conducted in Rwanda on the prevalence of helminth 
infections in HIV-positive pregnant females. However a study has been conducted on the 
prevalence of helminth infections in school children from eight districts in Rwanda where the 
prevalence was 64% [167], which is much lower than the 37.8% level observed in our study. 
This may be related to the greater recreational exposure of children to contaminated soil, as well 
as a reduced level of agricultural activities in pregnant females.  
Our findings show lower prevalence levels for malaria and malaria-helminths co-infection, but a 
higher level of helminthic infection than those reported in a study of pregnant women from 
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Ghana [74]. In that study the prevalence of malaria, intestinal helminths and dual infection was 
36.3%, 25.7% and 16.6% respectively. However, the HIV status of that population was not 
assessed. An investigation in Uganda among pregnant women [168] reported a prevalence level 
of 68% for helminthic infection and 11% for malaria, with 12% being HIV-positive. Thus, these 
studies show varying levels of helminths infection during pregnancy across African populations. 
There may be a number of reasons for this, including differences in socio-economic status and 
the level of helminths exposure. It should be noted, however, that in the present study all 
participants received ART, and we found that helminths seem to be susceptible to particular 
ART regimens. When comparing HIV-negative to HIV-positive pregnant females, malaria is 
more common in the latter group and helminth infection increases the risk of mother-to-child 
transmission of the virus [15].    
Our findings also show that dual infection with malaria and helminths is associated with a lower 
BMI compared to the other 3 study groups (Table 3.2). Women with malaria-only, helminth-
only, or dual infection all had lower haemoglobin levels than non-infected women, but the 
difference was only significant for helminth-only or dually infected subjects (Table 3.2). The 
dually infected subjects had the lowest haemoglobin levels. It has been observed that dual 
infection of malaria with helminths leads to lower haemoglobin levels when compared to 
malaria-only or helminth-only infected pregnant women, whilst all 3 infected groups exhibit 
lower haemoglobin levels compared to non-infected subjects [169]. The non-significant effect of 
malaria on haemoglobin levels within our study may be related to the lower number of subjects 
carrying only malaria, thus reducing the power of the analysis. 
In subjects with a helminth-only or a malaria-helminths infection, CD4 cell counts were 
significantly lower than in those with malaria-only or no infection (Table 3.2). It is well 
established that pregnancy, and first pregnancy in particular, increases malaria susceptibility 
[170]. It is equally generally accepted that HIV-infected pregnant women have a significantly 
increased risk of malaria parasitaemia and placental malaria, more severe clinical manifestations 
and pregnancy outcomes [169].Our study suggests that in HIV-positive pregnant women malaria 
is not necessarily associated with lower CD4 cell counts. This was confirmed by a multiple 
regression analysis in which the presence of malaria did not associate with CD4 counts. Further 
support for these results comes from a study showing that CD4 counts do not differ between 
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HIV-positive subjects with or without malaria [169], and from the observation that the 
prevalence of malaria is not related to CD4 cell counts [169]. Furthermore, a prospective 
investigation of HIV-positive pregnant women in Kigali, Rwanda, demonstrated that HIV-
positivity but not CD4 cell count was the only factor related to an increased risk of malaria 
[171,166]. One explanation could be the fact that HIV infection has been found to be associated 
with a specific cytokine dysregulation resulting from impairment of IL-12-mediated IFNγ 
production by intervillous blood mononuclear cells impairing the immune response against 
placental malaria, rather than mounting a generalized suppression of the cellular immune 
response against malaria [172-175]. Thus, regarding CD4 cell count level and malaria alone, 
there seems to be conflicting evidence blurring the otherwise clear-cut picture of the malaria-
HIV interaction.  
By contrast, our data also show that helminth infection is linked to lower CD4 cell counts in 
pregnant, HIV-positive women and that all subjects with a DVL tested positive for helminth. 
However, previous studies have shown that CD4 counts correlate positively with the risk of 
helminths infection [3,176] although others have found the opposite [178]. Reviewing the 
epidemiology and immunology of helminth-HIV interactions, one study concluded that there is 
inconsistent evidence for a beneficial effect of anthelminthic therapy on CD4 counts and viral 
load in HIV-1 co-infected individuals [178]. However, it could be expected that this effect would 
be suppressed by successful ART, reducing viremia and possibly explaining why, in some 
studies including ours, CD4 counts did not relate to increased helminthic infection risk. It should 
be noted that both the earlier studies were performed using subjects who were ART naïve, whilst 
our study only involved women who were already receiving ART. 
It has already been proposed that ART may reduce the prevalence of helminth infection [177]. 
However, the study by Bachur and colleagues compared ART with non-ART in different areas, 
and did not control for other covariates such as education and age, which could be relevant. A 
major finding of the study presented here is that there is a differential effect of ART on the 
helminthic infection rate. Thus, the ART regimens of AZT-NVP and d4T-3TC-NVP both 
significantly reduced the risk of helminthic infection compared to a regimen of AZT-3TC-NVP. 
This effect was particularly evident for Trichiuris trichiura. Furthermore, the d4T-3TC-NVP 
regimen, but not the AZT-NVP regimen, lowered the EPG count, suggesting that the first 
E. Ivan PhD thesis  Page 43 
 
therapy reduces both the prevalence and intensity of helminthic infection. The reason why these 
particular ARV regimens reduce the risk of Trichiuris trichiura infection is not known and 
requires future in vitro investigations.  
It was also observed that both ART regimens that reduced the risk of helminthic infection had 
similar but less prominent effects on malaria risk, and had lower prevalence levels of DVL than 
the AZT-3TC-NVP regimen. A number of in vitro studies have shown that protease inhibitors 
can inhibit P. falciparum growth [179,180]; however, similar studies have not been performed 
with the other antiretroviral drug classes. Clinical studies have confirmed the ability of ART to 
reduce malaria prevalence [128,180].  A recent study also showed that early initiation of ART 
was linked with reduced levels of detectable viral load in pregnancy in the context of an option B 
treatment program initiated in some countries including Rwanda [181].  
The present study found that different ART regimens were being used in urban compared to peri-
urban districts. The reasons for this difference are not known and are surprising in light of the 
Rwanda Ministry of Health’s nationwide treatment guidelines for HIV infection. It is possible 
that this difference may be related to supply chain problems with the AZT-NVP regimen being 
more accessible to peri-urban than rural areas.    
The strengths of this study reside in the screening of 3 stool samples collected from each subject 
on three consecutive days for the presence of helminths, and the use of a combination of two 
different screening techniques to increase the sensitivity of helminths and malaria diagnosis. 
However, this study also has some limitations. Due to its cross-sectional design, it is impossible 
to determine temporal direction or causality. Also, the study had no control group of HIV-
negative or positive subjects not receiving ART. Additionally, the sample size for this study was 
relatively small and therefore it may not have been sufficiently powerful to uncover true 
differences or relationships within the study cohort and may also obscure or falsely reveal 
significant effects in the logistic and multiple regression models.    
In conclusion, we found that the prevalence of malaria and helminthic infections is high in HIV-
positive pregnant women in Rwanda. Helminthic infection in this population is an important risk 
factor for low haemoglobin and CD4 cell counts whilst malaria-helminths dual infections are 
characterized by a reduced BMI. Particular ART regimens seem to have positive effects on both 
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P. falciparum and Trichiuris trichiura infections, and further studies on drug-drug interaction 
and association needs to be undertaken in large population samples for reproducibility and 
further confirm these results. 
The following chapter describes a cross sectional analysis of baseline data of a longitudinal study 
comparing targeted versus non-targeted anti-helminthic therapy in HIV-positive pregnant 
females receiving ART. The baseline analysis included a higher number of subjects (N=980) 
than the study described in the previous chapter allowing a more detailed analysis of the risk 
factors for helminthic infection including demographic factors and personal hygiene related with 
helminthic infection likely fuelling factors.   
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Chapter 4: THE PREVALENCE OF HELMINTH AND 
MALARIA INFECTION IN HIV-POSITIVE PREGNANT 
WOMEN ON ANTI-RETROVIRAL THERAPY IN RWANDA 
4.1 Abstract 
Background: Within sub-Saharan Africa, helminthic and malaria infections cause considerable 
morbidity in HIV-positive pregnant women and their offspring. Helminth infections are also 
associated with a higher risk of mother-to-child HIV transmission. The aim of this study was to 
determine the prevalence of, and the protective and risk factors for helminth and malaria 
infections in HIV-positive pregnant Rwandan women receiving anti-retroviral therapy (ART).  
Methods: Pregnant females (N=980) were recruited from health centres in rural and peri-urban 
locations in the central and eastern provinces of Rwanda. Helminths infection was diagnosed 
using the Kato Katz method whilst the presence of Plasmodium falciparum was identified from 
blood smears.  
Results: The prevalence of helminth infections was 34.3%, of malaria 13.3%, and of co-
infections 6.6%. Helminths infection were more common in rural (43.1%) than peri-urban 
(18.0%; p<0.0005) sites. A CD4 count ≤ 350 cells/mm3 was associated with a higher risk of 
helminth infection (odds ratio, 3.39; 95% CIs, 2.16-5.33; p<0.0005) and malaria (3.37 [2.11-
5.38]; p<0.0005) whilst helminth infection was a risk factor for malaria infection and vice versa. 
Education and employment reduced the risk of all types of infection whilst hand washing 
protected against helminth infection (0.29 [0.19-0.46]; p<0.0005). The TDF-3TC-NVP (3.47 
[2.21-5.45]; p<0.0005), D4T-3TC-NVP (2.47 [1.27-4.80]; p<0.05) and AZT-NVP (2.60 [1.33-
5.08]; p<0.05) regimens each yielded higher helminth infection rates than the AZT-3TC-NVP 
regimen. Anti-retroviral therapy had no effect on the risk of malaria.  
Conclusions: HIV-positive pregnant women would benefit from the scaling up of de-worming 
programs alongside health education and hygiene interventions. The differential effect of certain 
ART combinations (as observed here most strongly with AZT-3TC-NVP) possibly protecting 
against helminth infection warrants further investigation. The possibility of drug-drug 
interactions between albendazole, Coartem and ARTs deserves further investigation. 
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4.2 Introduction 
In sub-Saharan Africa, the health burden of helminthic disease is enormous and, consequently, 
co-infections with malaria against a backdrop of often-high HIV sero-prevalence are numerous 
[182], so that combating co-infections has been identified as an important public health goal 
[20,75]. Consequently, the important areas of current interest are the effects of helminthic 
infections on immune regulation, and their possible consequences for susceptibility to other 
infections and immunologically mediated conditions such as allergy and autoimmune diseases 
[183]. Risk factors for helminthic infections depend on the route of transmission and the life 
cycles of the various helminth species; they are usually related to hygiene and sanitation 
[104,178,184] The geographical distribution of helminthic infections is largely determined by 
several environmental factors such as climate and the presence of stagnant water bodies 
[18,185,186]. In the absence of vaccinations, the only currently recommended public health 
intervention for soil-transmitted helminths is regular mass de-worming, particularly for high risk 
groups, backed up by facilitating access to clean water, improved sanitation and health education 
[20,23,72,187]. 
Pregnancy may increase susceptibility to helminths, but this is uncertain. A recent study from 
Gabon showed increased prevalence of helminthiasis in pregnancy [188], but a study from 
Thailand found no association [184]. Susceptibility and clinical outcomes are further 
complicated by co-infection with HIV and malaria. Malaria due to P. falciparum, combined with 
helminthic infections during pregnancy in HIV-positive women is of great concern from a public 
health perspective [156,188,189]. Control of P. falciparum infection by intermittent preventive 
treatment and use of insecticide-treated bed nets is of great importance, especially in 
primigravidae [1,94,190-192]. HIV-infected women tend to experience faster CD4 decline 
during and after pregnancy [193], and could therefore be even more susceptible to helminthic 
infection and malaria.  
The objective of this cross-sectional observational cohort study was to assess the major risk 
factors for helminth and malaria co-infection in HIV-positive pregnant women who participated 
in an early anti-retroviral therapy (ART) initiation program for the prevention of mother-to-child 
transmission in Rwanda. We describe the prevalence of malaria and helminth infection in HIV-
infected pregnant women on ART, and assess the factors that may increase or decrease rates of 
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both infections. This cross-sectional investigation was a baseline study for a longitudinal cohort 
in which future measurements during pregnancy and post-delivery would be performed to 
determine the effect of anthelminthic intervention on helminth and P. falciparum infection rates 
and HIV disease progression.    
4.3 Methods 
4.3.1 Study population and procedures 
Ethical approval of the methodology was obtained from the Rwanda National Ethics Committee 
and the Ethics Committee (Human Research) of the University of the Witwatersrand Medical 
School, Johannesburg, South Africa. 
The participants in the study were recruited between 02 January 2010 and 29 December 2010 
from women accessing antenatal care and ART services at rural and peri-urban health centres in 
the central and eastern provinces of Rwanda. After giving written informed consent, women in 
the second trimester of pregnancy were enrolled at their fourth, fifth or sixth month of gestation. 
In addition, women were enrolled if they lived within walking distance of the study areas, and if 
they planned to deliver at the health centre registered for the study. Enrolment criteria were: HIV 
infection; pregnancy in the second trimester; use of ART; and willingness to provide three stool 
samples on consecutive days. Women were excluded if they were diagnosed with tuberculosis, 
or if they had taken any anti-helminthic drugs at any time prior to entry into the study. Those 
who had been enrolled in other research projects during the study period were also excluded. 
Upon enrolment, participants were interviewed to obtain demographic and socio-economic 
information pertaining to the relevant environmental risk factors for helminthic and malaria 
infections, (questionnaire used is attached as Appendix 3). Subsequently, participants provided 
blood and stool samples before being treated in accordance with the study protocol.  
4.3.2. Other procedures 
The other methods used in this section of the thesis are as follows: intestinal helminthic 
identification in stools; identification of P. falciparum infection; measurement of serum 
haemoglobin levels; assessment of CD4 counts; viral load measurement; treatment of helminthic, 
P. falciparum and HIV infections. All these methods are described in detail in Chapter 2 of this 
thesis.  
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4.3.3. Statistical analysis of data 
Data analysis was performed using Stata® version 11.0 (College Station, TX, USA) and 
Statistica® version 9.1 (StatSoft, Tulsa, OK, USA). Data that were not normally distributed were 
log-transformed to normality before analysis. Differences between percentage values were 
assessed using the χ2 test.  
Backward stepwise multiple logistic regression analysis was used to determine the principal 
factors associated with helminth and malaria infections and helminthic-malaria co-infections. 
Models were constructed for infection with each individual helminthic species, i.e. Ascaris 
lumbricoides, Trichiuris trichiura and hookworms, and a combined model for infection with any 
helminthic species. The independent variables included in the initial logistic regression models 
were, for helminthic infections: location, month of year, ART, number of pregnancies 
(gravidity), education, employment, water source, use of shoes, hand washing, dietary 
supplement use, viral load detection, presence/absence of malaria, age, height, gestational stage 
and CD4 counts. Effect modification between ART regimens and each of the other independent 
variables was assessed by including an interaction term in the model for any helminth infection. 
With malaria as the dependent dichotomous variable, the same list of independent variables was 
used. The presence/absence of helminthic infection was included as an additional independent 
variable, whilst presence/absence of malaria was removed. With helminthic-malaria co-infection 
as the dependent variable, both malaria and helminthic presence/absence were removed from the 
model. In all the logistic regression models, the independent variable with the highest p-value 
was removed until only variables with p<0.05 were left in the model.  
Backward stepwise multiple regression analysis was used to identify the principal determinants 
of faecal helminthic egg counts and blood haemoglobin levels. Univariate analyses were initially 
performed and any variable with p<0.50 was included as an independent variable in the multiple 
regression models. The same procedure as described for the logistic regression models was then 
followed. 
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4.4 RESULTS 
4.4.1 Prevalence of helminthic infections and malaria 
The data in Table 4.1 show that, in the presence or absence of malaria, infection with any 
helminth species occurred in 336 (34.3%) of the participating sample, being significantly 
(p<0.0005) more common in rural than in peri-urban communities. Infection with helminths in 
the absence of malaria showed a similar trend, occurring in 36.5% of rural and in 11.3% of peri-
urban subjects (p<0.0005).  
Table 4.1. Prevalence of helminth and malaria infections in rural and peri-urban areas 
VARIABLES RURAL PERI-URBAN COMBINED 
N 635 345 980 
Helminth with or without malaria 43.1 18.0*** 34.3 
Helminth species:   
Ascaris lumbricoides 26.1 11.0*** 20.8 
Trichiuris trichiura 8.66 4.35** 7.14 
Hookworm 8.35 2.61*** 6.33 
Malaria with or without helminths 11.0 17.4* 13.3 
Helminths with malaria 6.61 6.67 6.63 
All data expressed as a percentage; *p<0.05, **p<0.005, ***p<0.0005 vs. rural 
Infection with each of the three-helminth species also occurred more often in the rural than in the 
peri-urban sample, with A. lumbricoides being the most common. The presence of a malaria 
infection (in the presence or absence of a helminth) was more frequent in peri-urban than in rural 
subjects (p<0.05). This trend was mirrored by malaria-only infections, with a prevalence of 
4.41% in rural and 10.7% in peri-urban women (p<0.0005). The prevalence of helminth-malaria 
co-infection was similar in both environments (Table 4.1). 
4.4.2 Prevalence of helminthic infections and malaria in different population sub-groups 
Helminthic infections of any type, asymptomatic malaria or co-infections were all less prevalent 
in subjects receiving AZT-3TC-NVP when compared to those taking d4T-3TC-NVP (p<0.005) 
(see Table 4.2). Treatment with AZT-3TC-NVP was also associated with a lower prevalence of 
malaria co-infection when compared to AZT-NVP, and TDF-3TC-NVP therapy. The latter 
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therapy, on the other hand, was associated with a lower prevalence of asymptomatic malaria 
compared to the administration of AZT-NVP. 
 Table 4.2. Prevalence of helminth and malarial infections in relation to various risk factors 
All data expressed as percentages *p<0.05, **p<0.005, ***p<0.0005; For ART: *p<0.05, **p<0.005 vs. 
d4T-3TC-NVP; †p<0.05, †††p<0.0005 vs. AZT-NVP; ‡p<0.05 vs. AZT-3TC-NVP 
 
Compared to malaria or co-infection rates, a number of other factors had the opposite effect on 
helminthic infection. Thus helminthic infections were more common, but malaria and 
consequently co-infections with HIV were less common in the women who were tested between 
March and May compared to those tested in January or February. The same pattern was observed 
VARIABLES N HELMINTH (%) MALARIA (%) CO-INFECTION (%) 
ART 
AZT-3TC-NVP 299 27.4** 6.35**††† 2.67*††† 
AZT-NVP 126 32.5 24.6** 14.3** 
d4T-3TC-NVP 461 39.7 14.5 6.72 
TDF-3TC-NVP 94 31.9 13.8† 8.51‡ 
Months 
Jan-Feb 262 27.9 24.4 12.2 
Mar-May 718 36.6* 9.19*** 4.60*** 
Age 
≤ 30 years 545 37.4 10.3 5.50 
> 30 years 435 30.3* 17.0** 8.05 
Gravidity 
1 225 42.2 16.0 10.2 
2-5 755 31.9** 12.4 5.56* 
Gestational 
stage 
4 months 505 33.5 22.0 11.3 
5-6 months 476 35.2 4.00*** 1.68*** 
Education 
Some 480 21.6 10.6 2.80 
None 500 47.5*** 16.0* 10.6*** 
Employment 
Yes 181 28.3 10.9 3.63 
No 799 60.8*** 23.8*** 19.9*** 
Water 
Piped 215 13.0 16.7 3.26 
River 765 40.3*** 12.3 7.58* 
Shoe wearing 
Yes 380 30.5 16.3 8.16 
No 600 36.7* 11.3* 5.67 
Hand 
washing 
Yes 695 29.3 17.7 8.63 
No 285 46.3*** 2.46*** 1.75*** 
Diet 
supplements 
Yes 281 28.1 21.3 11.7 
No 699 36.8* 10.0*** 4.58*** 
Viral load 
Detectable 90 70.0 17.8 14.4 
No detectable 890 30.7*** 12.8 5.84** 
CD4 
≤ 350 cells/mm3 209 62.7 27.7 20.6 
> 350 cells/mm3 771 26.6*** 9.34*** 2.85*** 
Malaria 
Present 130 50.0 - - 
Absent 850 31.9*** - - 
Helminths 
Present 336 - 19.3 - 
Absent 644 - 10.1*** - 
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in women who did not wear shoes compared to those who did, and in women who did not 
regularly wash their hands or take dietary supplements compared to those that did (Table 4.2).  
Pregnant women who were older than 30 years at testing had a lower prevalence of helminthic 
infection, but higher levels of asymptomatic malaria compared to women who were 30 years or 
younger. Primigravidae had higher prevalence’s for all 3 infection types compared to women 
who had had more than one previous pregnancy, whilst women who presented for testing at an 
earlier stage of their pregnancy (4 months) had higher prevalence levels of malaria and co-
infections compared to those who were tested at a later stage (5-6 months) (Table 4.2).  
Study participants who were unemployed and subjects with no formal education had a higher 
prevalence of helminthic infections, malaria and co-infections compared to subjects who were 
employed, and educated, respectively. Women who used water directly from a river rather than 
piped water for their water needs had a higher prevalence of both helminthic infection and co-
infection, but a lower prevalence of malaria, although this last comparison did not reach 
statistical significance (p=0.09). A detectable viral load and a CD4 count ≤ 350 cells/mm3 were 
both associated with higher levels of all infections. Subjects with asymptomatic malaria had a 
higher prevalence of helminthic infections, and vice versa (Table 4.2). 
4.4.3 Identification of risk and protective factors for helminth infections 
Table 4.3 gives the results of multiple logistic regression analyses to identify risk and protective 
factors for helminth infections. With regard to ART, the d4T-3TC-NVP regimen groups 
exhibited higher prevalence’s of infection with A. lumbricoides and hookworm compared to 
AZT-3TC-NVP. The same applied with the AZT-NVP and TDF-3TC-NVP regimens regarding 
T. trichiura prevalence when compared to the AZT-3TC-NVP therapy. No interaction was 
observed between ART regimens and any of the other independent variables within the 
multivariable model for any helminth infection.  
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Table 4.3. Multiple logistic regression analyses to identify risk factors for helminth 
infections 
†As compared to AZT-3TC-NVP; data are odds ratios (95% confidence intervals); reference group for 
each variable is shown in bold in column 2; odds ratios are not given for variables that had no significant 
effect and were removed from regression model; the following variables did not significantly affect risk 
for any of the above infections: gestational stage, wearing shoes, use of dietary supplements and height; 
each of the helminth infections were used as the dependent variable in multivariable regression models 
adjusted for all the variables shown in each column. More details on how each model was developed are 
given in section 4.3.3;  *p<0.05, **p<0.005, ***p<0.0005. 
 
There were lower rates of hookworm infestation in subjects who were screened for infections 
during January and February compared to those screened later in the year, whilst subjects who 
were older than 30 years, or who were multigravidae had a lower risk of any helminthic infection 
when compared, respectively, to those 30 and younger, or primigravidae (Table 4.3).  
INDEPENDENT VARIABLES 
ODDS RATIOS 
FOR ASCARIS 
INFECTION 
ODDS RATIOS 
FOR 
TRICHIURA 
INFECTION 
ODDS RATIOS 
FOR 
HOOKWORM 
INFECTION 
ODDS RATIO FOR 
ANY HELMINTH 
INFECTION 
ART† 
d4T-3TC-NVP 
2.59 
(1.79-3.75)*** 
- 
2.19 
(1.27-3.79)** 
3.47 
(2.21-5.45)*** 
AZT-NVP - 
4.65 
(2.41-8.96)*** 
- 2.60 (1.33-5.08)* 
TDF-3TC-
NVP 
- 
3.57 
(1.69-7.57)** 
- 
2.47 
(1.27-4.80)* 
Months:  
Jan-Feb vs.  
Mar-May 
- - 
0.32 
(0.13-0.77) * 
- 
Age:  
>30 vs. ≤30 
yrs. 
- - - 
0.66 
(0.47-0.94)* 
No. of 
pregnancies 
>1 vs. 1 - - - 0.59 (0.39-0.87)* 
Location:  
Urban vs. 
Rural 
0.52 
(0.33-0.82)** 
- 
0.32 
(0.15-0.66)** 
0.41 
(0.27-0.62)*** 
Education:  Yes vs. No 
0.41 
(0.28-0.59)*** 
- - 
0.39 
(0.28-0.55)*** 
Employment:  Yes vs. No 
0.47 
(0.31-0.73)** 
0.14 
(0.08-0.27)*** 
- 
0.23 
(0.15-0.36)*** 
Water:  
Piped vs. 
River 
0.30 
(0.16-0.53)*** 
- - 
0.23 
(0.14-0.38)*** 
Hand washing:  Yes vs. No 
0.52 
(0.33-0.80)** 
0.20 
(0.10-0.40)*** 
- 
0.29 
(0.19-0.46)*** 
Detectable viral 
load:  
Yes vs. No 
1.95 
(1.11-3.42)* 
-  
2.42 
(1.29-4.55)* 
CD4:  
≤350 vs.>350 
cells/mm3 
2.12 (1.38-3.23)** 2.27 (1.32-3.90)** 
3.03 (1.75-
5.26)*** 
3.39 (2.16-5.33)*** 
Malaria:  
Infected vs. 
Not 
- - - 2.13 (1.27-3.59)** 
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Subjects who were residents of a peri-urban location had a lower risk of A. lumbricoides, 
hookworm or any helminthic infection compared to those from a rural environment. Educated 
study participants and those who used piped water were at a lower risk of A. lumbricoides or any 
helminth infection compared, respectively, to subjects with no formal education and those who 
used river water. Furthermore, pregnant women who were employed or who regularly washed 
their hands were at a lower risk for A. lumbricoides, T. trichiura or any helminth infection 
compared to subjects who, respectively, were employed or who did not wash their hands 
regularly (Table 4.3).  
Pregnant women who had a detectable HIV viral load compared to those who did not, were at a 
higher risk for A. lumbricoides, and subjects with a CD4 count at, or below 350 cells/mm3 were 
at a higher risk for all types of helminthic infections compared to those with CD4 counts above 
350 cells/mm3. The presence of malaria was associated with a higher risk of any helminthic 
infection (Table 4.3). 
4.4.4 Identification of risk and protective factors for malaria and co-infections 
The risk of malaria was higher in the months of January and February than in the months from 
March to May. Risk was also higher in older women but lower in those in the third trimester of 
their pregnancy. This latter trend was also mirrored by risk of co-infection. Co-infection risk was 
also reduced in subjects with some formal education and in those who were employed. Pregnant 
women who used piped rather than water directly from a river ran a higher risk of malaria. 
Helminthic infection was associated with a higher risk of malaria, whilst low CD4 counts were 
also linked to a higher risk of malaria and co-infection. Interestingly, women who regularly 
washed their hands ran a higher risk of both malaria and co-infections (Table 4.4).  
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Table 4.4. Multiple logistic regression analyses to identify risk factors for malaria infection 
and helminth-malaria co-infection 
VARIABLES ODDS RATIOS FOR 
MALARIA INFECTION 
ODDS RATIOS FOR 
HELMINTH-MALARIA 
CO-INFECTION 
Months:  Jan-Feb vs. Mar-May 1.70 (1.08-2.68)* - 
Age:  >30 vs. ≤30 years 1.76 (1.15-2.69)* - 
Gestational stage:  5-6 vs. 4 months 0.17 (0.10-0.29)*** 0.16 (0.07-0.35)*** 
Education:  Yes vs. No - 0.32 (0.17-0.63)** 
Employment:  Yes vs. No - 0.26 (0.14-0.49)*** 
Water:   Piped vs. River 1.76 (1.04-2.97)* - 
Hand washing:  Yes vs. No 5.81 (2.51-13.5)*** 2.96 (1.07-8.19)* 
Helminth infection: Yes vs. No 2.42 (1.51-3.89)*** - 
CD4:  ≤350 vs.>350 cells/mm
3
 3.37 (2.11-5.38)*** 7.13 (3.95-12.9)*** 
Data are odds ratios (95% confidence intervals); odds ratios are not given for variables that had no significant effect and were removed from 
regression model; The following variables did not significantly affect risk for any of the above infections: location, ART, viral load, number of 
pregnancies, wearing shoes, use of dietary supplements and height; *p<0.05, **p<0.005, ***p<0.0005. 
4.4.5 Identification of the principal determinants of faecal helminth egg count and 
haemoglobin level 
Backward stepwise multiple regression analysis demonstrated that faecal helminth egg counts 
were highest in women who were multigravidas, who did not wear shoes and who had low CD4 
counts (Table 4.5). Haemoglobin levels were lowest in women who had helminth or malaria 
infections, who had low CD4 counts and who were at a more advanced (5 or 6 months compared 
to 4 months) gestational stage.  
Table 4.5. Multiple regression models for determinants of helminth egg count and 
haemoglobin level 
MODEL 
NUMBER 
DEPENDENT  
VARIABLE 
INDEPENDENT 
VARIABLES 
BETA VALUE 
(P- VALUE) 
R FOR MODEL 
(P-VALUE) 
1 Egg count (log) 
No. of  pregnancies 0.17 (0.001) 
0.28 (<0.0005) Use of shoes -0.13 (0.01) 
CD4 count (log) -0.54 (0.03) 
2 
Haemoglobin 
level 
Helminths -0.67 (<0.0005) 
0.34 (<0.0005) 
Malaria -0.31 (0.01) 
CD4 count (log) 1.37 (<0.0005) 
Gestational stage -0.19 (0.02) 
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Coding for number of pregnancies: primigravida - 1, multigravida - 2; Coding for use of shoes: wear 
shoes - 1, do not wear shoes - 0; Coding for helminth or malaria: infected - 1, no infection - 0; Coding for 
gestational stage: 4 months - 1, 5 or 6 months - 2  
4.5 Discussion 
In this study, we determined the prevalence and identified protective and risk factors of 
helminthic, malaria and co-infections in HIV-infected pregnant women on ART in Rwanda. We 
found that helminthic infection was more prevalent in rural than in peri-urban settings. Poor 
education and unemployment were risk factors for both helminthic and P. falciparum infection, 
whilst hand washing protected against worm infections. Treatment of HIV with AZT-3TC-NVP 
was associated with a lower prevalence of helminthic infections. A CD4 count of ≤350 
cells/mm3 was associated with higher levels of all infections. Multiple linear regression analysis 
demonstrated that helminth egg counts (EPG) were highest in women who were multigravidae 
and haemoglobin levels were lowest in women who had helminthic or malarial infections. 
The prevalence of helminth infection was higher among rural than peri-urban participants, the 
most prevalent helminth species being A. lumbricoides followed by T. trichiura and hookworm 
species (Ancylostoma duodenale and Necator americanus) being the least common. This agrees 
with previous findings from the same location [188]. Our results are further supported by 
findings from an earlier study in the region, which indicated that A. lumbricoides and T. trichiura 
were more commonly found in Rwanda and Burundi than in most other East African countries 
[194] 
Our findings also show lower prevalence levels for malaria and malaria-helminthic co-infection 
than previously reported for pregnant women in Ghana, but higher rates of helminthic infections 
[74]. A study in Uganda [168,186,195] reported that the prevalence of helminth infection among 
pregnant women there was 68% and for malaria was 11%; however, only 12% of those women 
were HIV-infected. Not surprisingly, such results indicate that there are varying prevalence 
levels of helminthic infection during pregnancy across East African populations. It should be 
noted that in the Ghana study the HIV status of the participants was not known, whilst in our 
study all participants were HIV-infected and receiving ART.  
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An earlier study conducted in Kigali, Rwanda, of malaria prevalence in HIV-positive pregnant 
women reported that 8.0% of the study group had malaria [167]. It is well documented that 
pregnant women living in malaria-endemic areas have an increased risk of P. falciparum 
infection during pregnancy, but this usually remains asymptomatic. In the current study we 
found seasonal fluctuation, with the prevalence of asymptomatic malaria being higher in subjects 
tested in the months of January and February compared to those tested in March through to May. 
This may be due to the higher rainfall in January and February leading to greater numbers of 
mosquitoes. 
In the current study, we also found that pregnant women who were older than 30 years at the 
time of testing had a lower prevalence of helminthic infection, but higher levels of malaria 
compared to younger females. The helminth data is supported by a previous study from Uganda 
[196]. However, most studies show that malaria is also more common in younger, pregnant 
women [197] and similarly this difference may be related to a number of factors, including 
lifestyle and socio-cultural differences across the population groups included in these studies.  
Little data exists on the relationship between number of previous pregnancies and the risk of 
helminthiasis. One study shows no effect of pregnancy number on the risk of helminthic 
infection [75] whilst a second study demonstrates a higher risk of hookworm infection but a 
lower risk of A. lumbricoides infection in primigravidae compared to multigravida women [198]. 
The data from the current study suggest that primigravid females have a higher prevalence and 
risk of helminth infection compared to multigravida women. This is an important finding and 
suggests that de-worming programs should target such individuals. Our data also show a higher 
faecal egg count in women who have already had pregnancies compared to women in their first 
pregnancy. Thus, although multigravida women are at a lower risk of helminthiasis than 
primigravidae, when they do acquire a helminthic infection they have a higher intensity of 
infection than primigravid women.  
Women who presented for testing at an earlier stage of their pregnancy (4 months) had a higher 
prevalence of malaria and helminth-malaria co-infection than those at a later stage of pregnancy 
(5-6 months). This result is supported by findings from previous African studies [198]. 
Education and employment acted as protective factors against both helminthic infection and 
helminth-malaria co-infection. Earlier studies showed similar associations [22] suggesting that 
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socio-economic status is a strong modulator of disease risk. Helminth infection was shown to be 
more prevalent in subjects who did not wash their hands. Other studies [198] have shown that the 
risk of helminth infection is reduced in subjects who regularly wash their hands, more so in those 
who use soap [199]. Thus, simple changes in hygiene practice would be important for reducing 
the prevalence of helminth infection. In our analysis, however, hand washing was statistically 
significantly associated with an increased risk of malaria and consequently helminth-malaria co-
infection. This finding is surprising and difficult to understand. Also to be noted is the finding 
that the use of piped compared to open river water reduced the risk of helminthic infection, but 
seemed to increase the risk for malaria. Whilst improved access to clean water is known to 
reduce the risk for helminthic infection [200], the greater risk of malaria associated with hand 
washing and piped water is an unusual finding, with little data available in the literature to 
confirm these associations. We believe that we are dealing with a confounder, although it is 
apparently difficult to understand its nature, and neither an elevated social status nor local vector 
behaviour and distribution offer any clue to understanding this result. It may also be speculated 
that this involves standpipes, not in-door plumbing, and that stagnant pools are accumulating 
around the standpipes thus attracting malaria vectors and risks increment. Further investigation is 
required to fully understand these results. 
Helminth egg counts were highest in multigravidas who did not regularly wear shoes and who 
had low CD4 counts (Table 4. 5). Haemoglobin levels were lowest in women who had helminth 
or malarial infections or both, who had low CD4 counts and whose gestational stage was 5 or 6 
months. Based on the distinct mechanisms by which helminths and malaria affect haemoglobin 
levels, it can be speculated that their combined presence might interact to enhance the risk of 
anaemia when intensity is moderately higher than in light worm infection intensities.  
The relationship between helminthic infection, intensity and anaemia has been described in 
several settings in Africa as well as in South East Asia [104,201]. Although the women in our 
study group were all on ART, with some having received nutritional supplements as part of their 
antenatal care package, previous regional studies also reported lower haemoglobin levels 
associated with high prevalence’s of helminths and malaria [75]. Our findings are further 
supported by other studies [19,23], which report that pregnant women are known to exhibit 
fluctuating CD4 levels in pregnancy, which might expose them to a higher prevalence of 
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helminthic infection, leading to maternal anaemia. This could be explained by the fact that the 
immune system is impaired during pregnancy and therefore HIV positive pregnant women who 
live in highly helminthic and malaria endemic areas in sub-Saharan Africa are likely to be at 
increased risk for helminthic-malaria co-infections.  
In the present study the risk of helminthic infection was higher in women with a reduced CD4 
cell count, and in subjects with a detectable viral load. This is in agreement with previous studies 
conducted in pregnant women in Uganda [195] and Rwanda [202], where CD4 counts correlated 
negatively with the risk of helminthic infection. However, another study [74] has found the 
opposite, although this investigation was not carried out in pregnant women. Webb et al. [203] 
reviewed the epidemiology and immunology of helminthic–HIV interactions, and concluded that 
the data were too inconsistent to postulate a beneficial effect for anti-helminthic therapy on CD4 
counts and viral load in HIV-1 co-infected individuals.  
With regard to malaria, we found that a low CD4 count was associated with an increased risk of 
P. falciparum infection. This contrasted with findings from a very similar study performed in 
Rwanda, where no such association was found [166,202]. The discrepancy may be related to the 
lower power of the earlier investigation, as there is clear evidence from a number of studies that, 
particularly in pregnant women, HIV does lead to more malaria episodes [94,204]. 
The prevalence of helminthic infection was higher in subjects with malaria, and vice versa. A 
study conducted in Ghana on pregnant women also showed that helminthic infection increased 
the risk of malaria [74]. It is thought that helminthic infections have a number of effects on the 
immune system that lead to increased susceptibility to malaria [103,157]. 
In our study sample all subjects were taking ART irrespective of CD4 count, as prescribed by the 
current Rwandan Ministry of Health guidelines for the prevention of mother-to-child 
transmission of HIV [16]. Helminthic infections of any type, malaria, or helminthic-malaria co-
infections were all less prevalent in subjects receiving AZT-3TC-NVP compared to the other 
three ART regimens (Table 4 2). These effects remained significant for helminthic infections 
after adjusting for confounding variables in a logistic regression analysis (Table 4.3). However, 
the protective effect of AZT-3TC-NVP for malaria was not sustained in the logistic regression 
model (Table 4.4). An earlier study conducted among pregnant Rwandan women also 
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demonstrated that specific ART regimens seemed to reduce helminthic prevalence, but had less 
effect on malaria [205]. That study demonstrated that the AZT-3TC-NVP regimen was the least 
protective compared to the other therapies, i.e. AZT-NVP, d4T-3TC-NVP and AZT [205].  
This finding contradicts data from the current study and may be related to a much smaller sample 
size (N=328) in the earlier study compared to the current study (N=980). Whilst these findings 
suggest a possible anti-helminthic effect of certain ART combinations, there was no non-ART 
control ‘arm’ in either study, as neither study was designed to detect the effect of ART on the 
risk of helminthic infections. This finding of possible anti-helminthic effects of certain ART 
regimens does warrant further investigation.  
Although the ART-induced reconstitution of cellular immunity would probably be the main 
factor for reducing helminthic infections among HIV patients, earlier in vitro and in vivo 
investigations have indicated that HIV treatment, especially with protease inhibitors (PIs), could 
have a direct effect by killing off parasites, including malaria [179]. It had already been 
suggested that ART without PIs might reduce the prevalence of helminthic infection [206,202]. 
Thus, ART itself might have contributed to the decline in helminth prevalence, asymptomatic 
malaria or co-infection seen in our study. We hypothesize that the anti-mitochondrial toxicity of 
ART compounds may play a direct role here, a hypothesis for which support needs to be tested in 
future field trials, designed to address this question. The strengths of the current study lie in the 
screening of a large number of women from eight health centres catering to women of all socio-
economic classes; the screening for the presence of helminths of three stool samples on three 
consecutive days; and the combination of two different screening techniques to increase the 
sensitivity of helminth diagnosis. However, our study also has limitations. Methodologically its 
cross-sectional design makes it impossible to determine temporal causality, including the 
inability of multivariate models to adjust for all confounding factors. The Kato Katz method used 
to determine the number of helminth eggs could have underestimated the proportion of women 
with light hookworm infection. The study had no control group of HIV-positive subjects not 
receiving ART.   
In conclusion, we found that the prevalence of helminthic infections, malaria, and co-infections 
are common among HIV-positive pregnant women on ART in Rwanda. Helminthic and malarial 
infections in this population are important risk factors for low haemoglobin levels. Subjects with 
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low CD4 counts were at higher risk of infections, and helminthic infection is a risk factor for 
malaria. Education and employment were independent protective factors for helminthic infection 
and malaria, whilst hand washing reduced the risk only for helminthic infections. The possible 
anthelminthic effect of some ART combinations and probably the drug-drug interactions 
warrants further study.  
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5 Chapter 5: Effect of de-worming on markers of disease progression in 
HIV-1 infected pregnant women on ART: a longitudinal observational 
cohort study 
 
5.1 Abstract 
Background: De-worming individuals with HIV infection who are also receiving ART may be 
of benefit, particularly in pregnant females. Therefore, the aim of this study was to determine the 
efficacy of targeted versus non-targeted anti-helminth therapy. The study outcomes were to 
measure the effects of anthelminthic therapy on Plasmodium falciparum infection, helminth 
infection haemoglobin levels, CD4 counts and viral load levels in pregnant, HIV-positive 
females receiving ARTs.   
Methods: A cohort of 980 HIV-infected pregnant women receiving ART were tested for 
helminth infection, malaria, CD4 counts, and haemoglobin levels at two visits during pregnancy 
and two visits postnatally, within 12 weeks between each visit. The women were given anti-
malarial drugs whenever they tested positive for malaria, and were randomised to either a 
targeted (n=467) or non-targeted (n=513) anthelminthic intervention with albendazole therapy.  
Results: No significant differences were noted between the targeted and non-targeted 
albendazole treatment arms for any of the variables measured at each study visit except for CD4 
counts, which were lower (P<0.05) in the latter compared to the former group at the final visit. 
Albendazole therapy was associated with favourable changes in haemoglobin levels, CD4 counts 
and viral loads, particularly in those subjects with helminthic infections. However, co-therapy of 
albendazole with anti-malarial (Coartem: artemether-lumefantrine) increased the risk of P. 
falciparum infection when compared to no therapy (OR [95% CIs] =5.51 [1.99-15.3]; p<0.005). 
Conclusions: Anti-helminthic therapy reduces detectable viral loads, and increases CD4 counts 
and haemoglobin levels in subjects with helminth infections receiving ART. However, 
albendazole therapy used in conjunction with Coartem is associated with an increased risk of 
malarias but further studies are required to confirm this data to rule out drug –drug interaction 
and other factors.  
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5.2 Introduction 
Public health strategies such as preventive chemotherapy aim to reduce the burden of helminthic 
diseases and are pertinent in Africa where over 22 million people are estimated to be co-infected 
with helminths and HIV-1 [207]. Co-infection commonly affects the natural history and disease 
progression of both helminthic infections and HIV [4,156,169]. However, the effects of 
interaction between the two infections are still little explored. Findings from observational 
studies and randomized control trials (RCTs) have shown impaired immune response to HIV in 
individuals with helminthic co-infection [13,94], suggesting that helminths play a role in 
immunity attenuation [35], HIV pathogenesis and disease progression [1,13,94,208–210]. 
Furthermore, findings from randomised control trials suggest that treatment of helminth co-
infection might delay HIV disease progression [5,8,211,212]. The immune interplay between 
helminthic infections and HIV is complex, and there are different hypotheses about the influence 
of these infections on each other, the most described influence being the Th2 bias induced by 
helminthic infections, suppressing Th1 responses specific to HIV, thereby leading to more rapid 
HIV progression [13,94,213]. Acquisition of HIV was found to be positively correlated with 
female urogenital schistosomiasis [20,214] but a RCT showed in contrast no benefit of de-
worming on the prevention of mother-to-child transmission of HIV [168,211]. Other systematic 
reviews described the effect of anti-helminthic treatment on markers for HIV disease 
progression, with lower increases in HIV viral loads and increases in CD4 counts being reported 
[1,79,203]. However, results from a more recent study did not suggest a beneficial role for de-
worming in HIV-positive subjects who were not eligible for anti-retroviral therapy (ART) [211]. 
However, other plausible reasons have linked malaria and helminths in HIV infected individuals 
[75], and the dual interactions consistently exhibit a high degree of prevalence of co-infection 
with HIV [215]. Findings suggest that helminths can affect HIV/AIDS, and malaria disease 
progression [216–222]. Data suggests that a combination of immunological, epidemiological, 
and clinical factors can contribute to these interactions and leads to a worsening prognosis for 
people affected by HIV/AIDS and malaria [156,223]. Studies suggest that helminths skew the 
immune response towards Th2 cells characterized by higher levels of interleukins IL-4, IL5, and 
IL13 [35,223].Together these studies highlight the impact of the high prevalence of these NTDs 
combined with their immunological effects on human hosts co-infected with HIV, which 
presents opportunities to design new strategies for the combied control of these diseases. 
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A recent study, conducted within districts of Rwanda where helminthic infection is endemic, 
showed a high rate of HIV and helminthic co-infection (37.8%) in pregnant females receiving 
ART [224]. During pregnancy such co-infection increases the risk of both anaemia and mother-
to-child transmission of HIV [156]. However, there is a paucity of data from African settings to 
give insights into whether HIV-infected pregnant women in ante- and postnatal settings receiving 
ART may benefit from de-worming. The aim of the current study was to determine the effect of 
de-worming among HIV-infected pregnant Rwandan women receiving ART on markers of HIV 
disease progression and haemoglobin levels. A further aim was to determine the efficiency of de-
worming using albendazole (ABZ) in targeted versus non-targeted treatment arms.  
5.3 Methods 
5.3.1 Study population 
Pregnant women from rural and peri-urban areas were recruited at local antenatal clinics. 
Inclusion criteria were HIV infection; pregnancy in the second trimester; use of ART and 
willingness to provide three stool samples on consecutive days. Women were excluded if they 
were diagnosed with tuberculosis, or if they had taken any anti-helminthic drugs at any time 
prior to entry into the study. Measurements were taken at two visits during pregnancy and two 
visits postnatally, with 12 weeks between each visit. Ethical approval was obtained from the 
Rwanda National Ethics Committee (RNEC) and the Ethics Committee (Human Research) of the 
University of the Witwatersrand Faculty of Health Science in Johannesburg, South Africa.   
5.3.2 Therapies 
With computer-generated random ID numbers, patients were assigned to a targeted de-worming 
treatment arm (n=550) with 400 mg albendazole (ABZ) given at any study visit if participants 
were helminthic positive, or an untargeted de-worming treatment arm (n=550) where all women 
were given 400 mg ABZ at each visit irrespective of their helminthic status. If they tested 
positive for P. falciparum at any of the 4 study visits, the women received Coartem (120mg 
artemether and 20mg lumefantrine per tablet). At all of the 4 visits to the antenatal clinics 
research assistants observed the taking of the all the study drugs by the study participants. All 
women received nevirapine for the prevention of mother-to-child HIV transmission and 
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subsequent combination ART, irrespective of CD4 cell levels − in accordance with the latest 
Rwandan Ministry of Health treatment guidelines of 2010 [225]. 
5.3.3 Measurements taken at each study visit 
We measured CD4 cell counts and serum haemoglobin levels at every visit, as were weight and 
height for the calculation of BMI. Viral loads were measured at baseline and at the final visit. 
Due to ART, viral loads were low and were therefore recorded as a categorical variable, being 
either above or below the detectable limit of 40 copies per mL. The presences of helminthic 
(Ascaris lumbricoides, Trichiuris trichiura and hookworms) and P. falciparum infections were 
assessed at every study visit, irrespective of whether they were in the targeted or untargeted ABZ 
treatment cohort. The methods used for all these measurements are described in Chapter 2 of this 
thesis, and a related publication [226] and the STROBE guidelines for observational cohort 
studies were followed (http://www.strobe-statement.org). 
5.3.4 Study sub-groups 
Initial analysis involved the comparison of the targeted with the non-targeted treatment arm. 
Taking advantage of the study format, we also performed a sub-group analysis in which 
participants were divided into 3 groups based on the frequency of the ABZ treatment. These 
groups consisted of:  
1. A control group (H-all ABZ-all) in which all subjects were helminth-free and received no 
ABZ throughout the study;  
2. A group in which all subjects were helminth-free but did receive ABZ throughout the study 
(H-all ABZ+all);  
3. A group in which all participants were helminth-infected at baseline and received ABZ 
therapy, either at all visits or only at visits where helminth infection was detected 
(H+ABZ+). 
These groups allowed us to determine the effect of ABZ therapy in the absence of a helminth 
infection (H-all ABZ+all) and to observe the effect of untreated helminth infection at baseline 
and the subsequent effects of ABZ therapy (H+ABZ+).   
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5.3.5 Statistical analyses 
Variables that were not normally distributed were log-transformed to normality before analysis, 
and are expressed in medians [interquartile range] in the tables. Normally-distributed data are 
expressed as mean ± SD. Comparisons between the targeted and non-targeted groups at each 
time point were made using Students t-test for continuous variables, whilst within-group 
comparisons were made using a paired Students t- test with Bonferroni correction for multiple 
testing. Comparisons at each time point for the sub-group analysis were performed using 
ANOVA followed by a Turkeys’ post hoc test. Categorical variables were analysed using the χ2 
test. Logistic regression was used to determine the effects of the ABZ and Coartem therapies on 
the risk of P. falciparum infection at visit 4 by dividing the cohort into 4 groups based on 
therapies received at visit 3: those who received neither treatment (reference group); those who 
received only ABZ; those who received only Coartem; those who received ABZ and Coartem.  
Backward, stepwise multivariable linear regression analysis was used to determine the correlates 
of percentage changes in haemoglobin levels and CD4 counts between visit 1 and visit 2. The 
reason for using this time period was that it covers the outcome of treatment of more long-term 
helminthic or P. falciparum infections than would be observed at other periods in the study, and 
would give a more accurate picture of response to therapy in subjects who had not previously 
been treated with anti-helminthic medication. The initial regression models included variables 
that correlated (p<0.50) in univariate correlation analyses with each of the 2 outcome variables. 
All statistical analyses were performed using Statistica version 9.1 software (StatSoft, Tulsa, OK, 
USA). 
5.4 Results 
5.4.1 Recruitment and loss to follow up 
A total of 1300 pregnant women were enrolled and assessed for eligibility. However, 200 
participants were excluded because they did not meet the study inclusion criteria. The resulting 
1100 eligible participants were 1:1 equally randomized to targeted and non-targeted treatment 
arms. A total of 121 subjects (12.3%) did not complete the study due to various reasons (see Fig 
5.1) and were excluded from the final analysis. Extra details on sample size estimation is given 
in Chapter 2, page 18, section 2.2.3. 
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Figure 5.1. Study flow diagram 
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5.4.2 Helminths, malaria and hemoglobin in targeted and non-targeted groups 
At baseline the only differences between the 2 groups were that the targeted had less subjects 
receiving AZT-3TC-NVP therapy than the non-targeted group (27.4 vs 33.3%; p=0.04) whilst 
the non-targeted group had less subjects receiving AZT-NVP therapy (10.7 vs 15.2; p=0.04). In 
addition more subjects in the targeted group had malaria-helminth co-infections (see below). 
The data in Fig 5.2A shows that the prevalence of helminthic infection in the targeted and non-
targeted study arms was similar at all-time points. In both groups helminthic infection dropped 
dramatically (p<0.0005) by visit 2 from that at visit 1 for both comparisons, with a shallower 
decrease by visit 4. The prevalence levels of individual helminthic infections at baseline for the 
total cohort (N=980) were as follows: A. lumbricoides, 20.8%; T. Trichiura, 7.14%; hookworm 
species, 6.33%. The prevalence of P. falciparum infection was similar at all-time points for the 
two treatment arms, with a significant fall in prevalence by visit 2 in both arms. However, there 
was a tendency for the infection rate to be higher at visit 4 in the non-targeted arm (7.8% vs. 
5.1%; p=0.09) (Fig 5.2B). The baseline prevalence of helminthic co-infection with P. falciparum 
was significantly higher in the targeted (8.60%) compared to the non-targeted group (4.90%; 
p<0.05), but for both groups no co-infection was detected at any of the subsequent visits. 
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Figure 5.2. Comparison of targeted (hashed line) versus non-targeted (solid line) treatment arms on helminth 
infection (A), P. falciparum infection (B), serum haemoglobin level (C) and CD4 count (D)
Data expressed as % for helminth and P. falciparum infections and as means for haemoglobin 
levels. The SD values were not included to aid clarity; 
y
p<0.05, 
yyy
p<0.0005 vs. preceding visit 
of non-targeted arm; 
z
p<0.05, 
zzz
p<0.0005 vs. preceding visit of targeted arm. 
Haemoglobin levels were similar in both arms at all study visits (Fig 5.2C), rising significantly 
from visit 1 to visit 2 in both arms, and peaking by visit 3. Thereafter, levels fell significantly 
(p<0.0005 for both comparisons) for visit 4. 
5.4.3 Baseline comparison of 3 study sub-groups 
The results in Table 5.1 show that at baseline (visit 1) no significant differences across the 3 
study groups were noted for age, gestation or BMI. The prevalence of multigravidity was higher 
in the H-all ABZ+all group when compared to the H+ABZ+ group (p<0.05). Baseline 
haemoglobin levels and CD4 counts, and the prevalence of detectable viral loads and malaria are 
also shown in Fig 3 and are discussed in the following section. The use of the 4 different ART 
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regimens did differ across the 3 study groups with the AZT-3TC-NVP regimen being more 
common in the H-all ABZ-all and H-all ABZ+all groups. The D4T-3TC-NVP regimen was 
found less often in the H-all ABZ-all and H-all ABZ+all groups when compared to the 
H+ABZ+group. No differences were noted for the use of the TDF-3TC-NVP or AZT-NVP 
regimens. The prevalence of some level of formal education, employment and peri urban 
residence was all lower in the H + ABZ + compared to the other 2 groups.  
Table 5.1. Baseline characteristics of study groups 
VARIABLES 
Subject groups 
H-all ABZ-all H-all ABZ + all H+ABZ+ 
N 204 272 334 
Age (years) 30.5 ± 4.62 30.3 ± 4.78 29.9 ± 4.73 
Gestation (months) 4.58 ± 0.72 4.65 ± 0.74 4.64 ± 0.72 
Gravidity >1 (%) 77.9 80.9* 71.6 
BMI 25.4 ± 3.27 25.2 ± 3.32 25.3 ± 3.28 
Haemoglobin (g/dl) 12.2 ± 1.18*** 12.3 ± 1.22*** 11.4 ± 1.35 
CD4 (cells/mm3) 489 [173]*** 483 [182]*** 380 [112] 
Detectable HIV (%) 4.90*** 4.78*** 18.9 
ART regimen (%): 
   AZT-3TC-NVP 
   AZT-NVP 
   D4T-3TC-NVP 
   TDF-3TC-NVP 
 
35.3* 
11.8 
42.1** 
10.8 
 
39.7*** 
9.55 
42.3** 
8.45 
 
24.2 
12.3 
54.8 
8.68 
Malaria (%) 8.33*** 9.93** 19.5 
Education (%) 60.8*** 57.0*** 32.0 
Employment (%) 88.2*** 90.1*** 67.1 
Peri-urban (%) 46.1*** 39.0*** 18.6 
 
Data given as %, mean ± SD or median [interquartile range]; H-all ABZ-all = helminth free and not treated with ABZ at any 
visits; H-all ABZ+all = helminth free and treated with ABZ at all visits; H+ABZ+ = infected with helminth at baseline and 
treated with ABZ;***p<0.0005, **p<0.005, *p<0.05 vs H+ABZ+  
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5.4.4 Longitudinal changes in malaria, haemoglobin, detectable viral load and CD4 counts 
in 3 study sub-groups 
The study variables at each visit for the 3 treatment sub-groups are shown in Fig 5.3. Helminth 
infection by definition was 100% in the H+ABZ+ group and 0.00% in all other groups at 
baseline and remained at 0.00% at all subsequent visits for the H-all ABZ-all and H-all ABZ+all 
groups. Within the H+ABZ+ group helminth infection fell to 5.99% at visit 2 (p<0.0005 vs. visit 
1), rose to 10.8% at visit 3 (p<0.05 vs. visit 2) and fell to 7.78% at visit 4 (p=0.10 vs. visit 3). 
Malaria was significantly more prevalent at the baseline visit for the H+ABZ+ group when 
compared to each of the 2 other groups (p<0.05 and p<0.0005 for the 2 comparisons) (Fig 5.3A). 
However, at visit 2 P. falciparum detection fell significantly in the former group (p<0.0005) to 
levels comparable to that of the other 2 groups, and remained so at visit 3. The prevalence of P. 
falciparum positivity rose slightly by visit 4 in both groups receiving ABZ therapy, but fell in the 
group not receiving ABZ (H-all ABZ-all), such that this group had a significantly (p<0.05) lower 
level of infection compared to the H+ABZ+ group at the final visit. In order to determine 
whether the rise in P. falciparum infection at visit 4 in those receiving ABZ therapy was due to 
an interaction between ABZ and Coartem therapy, a logistic regression analysis was performed. 
This demonstrated that subjects receiving both ABZ and Coartem at visit 3 had an odds ratio 
[95% CIs] for P. falciparum infection at visit 4 of 5.51 [1.99-15.3] (p<0.005) versus subjects 
receiving neither therapy. Subjects receiving Coartem only or ABZ only had odds ratios of 3.48 
[0.94-12.9] (p=0.06) and 1.68 [0.93-3.03] (p=0.08), respectively. Addition of possible 
confounders to the logistic regression models i.e. gravidity, gestational age at baseline, 
employment status and ART regimen did not negate this effect.  Haemoglobin levels were 
significantly lower in the H+ABZ+ group at baseline when compared to the 2 other sub-groups 
(p<0.0005 for both comparisons; Fig 5.3B) but rose significantly at visit 2 (p<0.0005) and visit 3 
(p<0.0005). Within the remaining 2 study groups, haemoglobin levels did not rise significantly 
between visits 1 and 2 but did so between visits 2 and 3 (p<0.005 and p<0.0005 for the 2 
comparisons). Haemoglobin levels fell significantly (p<0.0005 for both comparisons) between 
visits 3 and 4 in the H-all ABZ-all and H-all ABZ+all groups, but not in the H+ABZ+ group. 
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Figure 5.3: Sub-group analysis of malaria prevalence (A), haemoglobin levels (B), CD4 
counts (C) and prevalence of detectable viral loads (D) across study visits
 
Data expressed as % for malaria and detectable viral load and as means for haemoglobin levels and medians for 
CD4 counts. The SD and IQR values were excluded to aid clarity. Small dashes with diamond markers: H-all ABZ-
all = helminth free and not treated with ABZ at any visits; solid line with circle markers: H-all ABZ+all = helminth 
free and treated with ABZ at all visits; Large dashes with triangle markers: H+ABZ+ = infected with helminth at 
baseline and treated with ABZ; 
a
p<0.05, 
aa
p<0.005, 
aaa
p<0.0005  H+ABZ+ vs H-all ABZ-all; 
b
p<0.05, 
bb
p<0.005, 
bbb
p<0.0005, H+ABZ+ vs H-all ABZ+all; 
w
p<0.05, 
www
p<0.0005 vs preceding visit within H+ABZ+ group; 
yy
p<0.005, 
yyy
p<0.0005 vs preceding visit within H-all ABZ+all group; 
zz
p<0.005, 
zzz
p<0.0005 vs preceding visit 
within H-all ABZ-all group. 
 
The CD4 counts were significantly lower in the H+ABZ+ group at baseline when compared to 
the 2 other sub-groups (p<0.0005 for both comparisons (Fig 5.3C). The CD4 counts rose 
significantly (p<0.0005) within this group from visit 1 to 2 and (p<0.05) from visit 2 to visit 3, 
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but at both visits the CD4 levels were still significantly (p<0.0005 for all 3 comparisons) lower 
when compared to the 2 other sub-groups. However, a large (p<0.0005) increase in CD4 counts 
from visit 3 to visit 4 brought levels to within the range observed in the other groups. There was 
a shallow but significant rise in CD4 counts from visit 1 to visit 3 in the H-all ABZ-all and H-all 
ABZ+all groups. The CD4 counts rose significantly (p<0.0005) from visit 3 to visit 4 in the H-all 
ABZ+all group leaving levels significantly (p<0.05) higher than in the H+ABZ+ group. 
The prevalence of detectable viral levels was significantly (p<0.0005 for both comparisons) 
higher in the H+ABZ+ group at baseline when compared to the 2 other groups, but fell 
significantly (p<0.0005) by visit 4 (Fig 5.3D). The prevalence of detectable viral loads did not 
change between the first and final visits for the 2 other study groups. 
5.4.5 Multivariable linear regression analyses 
The results of multivariable, backward, stepwise linear regression analyses for determining the 
correlates of percentage change in CD4 counts and percentage changes in haemoglobin level are 
shown in Table 5.2. These data show that, over the time period from visit 1 to visit 2, loss of a P. 
falciparum infection was associated with an increase in the percentage change in CD4 counts by 
8.64% (p<0.0005) whilst gain of an infection can reduce CD4 counts by 9.81% (p<0.0005) when 
compared to subjects with no change in infection status between these 2 study visits. Similar 
results were found for A. lumbricoides infections, with a loss of infection being associated with 
an increase in the percentage change in CD4 counts of 6.74% (p<0.0005) and a gain in infection 
leading to a fall in CD4 counts by 7.37% (p=0.003). Loss of a T. trichiura or a hookworm 
infection caused an increase in CD4 counts of 5.28% (p=0.02) and 5.94% (p=0.02), respectively. 
Subjects in whom a detectable viral load was observed at visit 1 had a 25.0% increase in CD4 
counts (p<0.0005) when compared to subjects with no detectable viral load. The independent 
variables within the model for percentage change in CD4 counts explained 22.0% (p<0.0005) of 
the variance in the dependent variable 
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Table 5.2. Backward, stepwise multivariable regression models for % change in CD4 
counts and haemoglobin levels from visit 1 to visit 4 
 
Variable coding: loss or gain of any helminth or P. falciparum infection was coded as -1 and +1 respectively and 
compared against no change in infection status (coded as 0); presence of a detectable viral load at visit 1 was coded 
as 1 whilst an undetectable viral load was coded as 0; periurban coded as 1 and urban as 0; employed coded as 1 and 
unemployed as0; gestational age of 5 or 6 months coded as 1 and gestational age of 4 months coded as 0 
 
Table 5.2 shows that periurban compared to urban-dwelling subjects had a 1.90% haemoglobin 
decline (p=0.01) between the study visits. Employed women had a 2.13% haemoglobin increase 
DEPENDENT 
VARIABLES 
INDEPENDENT VARIABLES WITH 
UNSTANDARDIZED BETA 
COEFFICIENT (P VALUE) 
ADJUSTED R
2
 
FOR FULL 
MODEL (P 
VALUE) 
Percentage change in 
CD4 count 
Loss of malaria infection       8.64 (<0.0005) 
0.22 (<0.0005) 
Gain in malaria infection       -9.81 (<0.0005) 
Loss of Ascaris infection       6.74 (<0.0005) 
Gain in Ascaris  infection      -7.37 (0.003) 
Loss of Trichuris infection       5.28 (0.02) 
Loss of hookworm 
infection        
5.94 (0.02) 
Detectable viral load at 
visit 1        
25.0 (<0.0005) 
Percentage change in 
haemoglobin level 
Peri-urban vs. rural -1.90 (0.01) 
0.09 (<0.0005) 
Employment 2.13 (0.02) 
Gestational age         2.08 (0.002) 
Gain of malaria infection       -3.82 (0.009) 
Loss of Ascaris infection        4.93 (<0.0005) 
Loss of Trichuris infection        2.93 (0.03) 
Loss of hookworm 
infection        
8.96 (<0.0005) 
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compared to unemployed women (p=0.02). Malaria between study visits 1 and 2 was associated 
with a 3.82% haemoglobin decrease (p=0.009). Successful treatment of A. lumbricoides, T. 
trichiura or hookworm infections were associated with 4.93% (p<0.0005), 2.93% (p=0.03) and a 
8.96% (p<0.0005) haemoglobin gain.  
5.5 Discussion 
The present study is the first to determine the effect of ABZ therapy on CD4 cell counts, viral 
loads and haemoglobin levels in HIV-infected pregnant women, who were also receiving ART 
and anti-malarial medications. Favourable changes were observed in all these variables over a 
period of 1 year, particularly in those subjects who had a helminthic infection at the baseline 
visit. The anti-helminthic therapy was administered in either a targeted or non-targeted fashion, 
and both these treatment arms were equally effective. However, P. falciparum infection levels at 
the final study visit were found to be higher in subjects receiving both ABZ and anti-malarial 
therapy (artemether with lumefantrine).          
This study was conducted in regions of Rwanda where helminthic infection is endemic, and 
under such conditions non-targeted anti-helminthic therapy may be more cost effective than a 
test-then-treat procedure. However, it is important to determine whether non-targeted therapy is 
efficacious and safe. The results from the present study suggest that this is the case, with the 
prevalence of helminth infection being comparable at all-time points in the two treatment arms, 
and the absence of any participant withdrawal due to adverse reactions to the ABZ therapy. 
Studies investigating the effect of deworming on CD4 cell counts and viral loads in HIV-positive 
patients have been analysed in a systematic review, which demonstrated a significant and 
beneficial effect [3,60,227]. Data from the current study support these findings and demonstrate 
that, in pregnant females receiving ABZ therapy, CD4 counts increase and the prevalence of 
detectable viral loads fall in the presence of concurrent ART. Thus, ABZ therapy significantly 
augments ART in improving immune function and blocking viral replication. Furthermore, 
haemoglobin levels also increase after initiation of anti-helminthic therapy. A recent study has 
shown that anti-helminthic therapy in HIV-positive pregnant females reduced viral load, but the 
effect was not statistically significant [207]. However, this study involved only 1 dose of ABZ or 
praziquantel, which was administered at baseline (second or third trimester of pregnancy), and 
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measurement of changes in viral load, but not CD4 counts, at 6 weeks’ post-treatment and at 
delivery. Furthermore, no participants were receiving ART at recruitment but were given single 
dose intrapartum and neonatal NVP to reduce mother-to-child transmission. Another study has 
also shown that, in HIV-positive subjects not receiving ART, ABZ therapy had no effect on 
HIV-associated disease progression [168]. However, as stated above, a meta-analysis of 3 
randomized controlled trials has shown benefits of anthelminthic therapy in HIV-positive 
subjects [89]. These contradictory data may result from differences in study format and 
methodology, including treatment of different helminth species, variable sample sizes, 
differences in study duration and frequency of anti-helminthic therapy, presence of different 
parallel therapies (e.g. for HIV or P. falciparum infection), variations in the prevalence of 
helminthic infections, and differences in population ages and genders. 
The current study demonstrates that increases in CD4 counts occur with the removal of each of 
the 3-helminth species measured, i.e. A. lumbricoides, T. trichiura and hookworm. The effects 
were significant, with the loss of each helminth infection causing a 5-7% increase in CD4 counts 
over a 3-month period. One other study has shown that treatment of A. lumbricoides with ABZ 
does improve CD4 counts [228,229] but these findings, or those for treatment of T. trichiura and 
hookworm observed in our study, are not supported by other reports [230]. It is interesting to 
note that none of these other studies included subjects receiving ART. It is therefore possible that 
ABZ therapy has a more significant effect on the immune system responsiveness of HIV-
infected subjects in the presence of ART. However, it must be noted that one reported study [72] 
did demonstrate a positive effect of ABZ therapy in subjects not receiving ART. More studies 
are therefore required to compare the effect of ABZ on HIV-associated disease progression in 
helminthic-infected, HIV-positive subjects receiving or not receiving ART.   
An interesting observation from the present study is that CD4 counts were higher at visit 4 in the 
non-targeted than in the targeted ABZ-treatment arm. The sub-group analysis demonstrated that 
this was due to a significant increase of CD4 counts between visit 3 and visit 4 in the subjects 
receiving ABZ therapy in the absence of any detectable helminthic infection. This suggests that 
ABZ may have an effect on CD4 counts that is independent of its ability to clear a worm 
infection. Another possible explanation for these results is that there may have been helminths 
present that were below the limit of detection of the stool microscopy, or that other parasites that 
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we were not set up to detect were being cleared by the ABZ therapy. A previous study of HIV-
infected pregnant women demonstrated that viral loads fell in subjects treated with ABZ 
irrespective of the presence of a helminthic infection [55,214].These data also suggest a direct 
effect of ABZ on immune function in HIV-infected subjects, but the mechanisms involved are 
not known. However, it is interesting to note that ABZ does have non-helminthic effects, as is 
shown by its ability to bind mammalian tubulin [231,232] and to inhibit vascular endothelial 
growth factor (VEGF) production [231]. 
Our study further confirms the higher prevalence of P. falciparum in subjects carrying a 
helminth infection [156]. Data from our investigation also shows that, at the final study visit, the 
prevalence of P. falciparum infection was higher in the non-targeted than in the targeted arm. 
The data from the sub-study analysis confirmed that this was due to a significantly higher 
prevalence of malaria in subjects receiving both ABZ and Coartem, suggesting a drug-drug 
interaction. An in vitro study has shown that exposing a human hepatoma cell line, HepG2, to 
ABZ does induce increased expression of cytochrome P450 enzymes [233]. Such enzymes are 
known to be responsible for the hepatic metabolism of anti-malarial drugs such as artemether and 
lumefantrine [234–236], which are the active constituents of Coartem. Thus, there is some 
experimental evidence suggesting that ABZ may lead to increased hepatic metabolism of the 
anti-malarial agents used in this study. However, pharmacokinetic investigations are required to 
confirm these results. 
Treatment with ABZ led to increases in serum haemoglobin levels, particularly in subjects 
carrying helminthic infections. Linear multiple regression analyses demonstrated that removal of 
helminthic and P. falciparum infections independently led to increases in serum haemoglobin 
levels. Both these types of parasitic infection are known to cause anaemia [230,237]. 
Haemoglobin levels increased postpartum, reaching a maximum at 3 months, and then falling to 
a nadir at 6 months. A previous study has demonstrated rising haemoglobin levels postnatally, 
but no decline in levels was observed at 6 months [75,168].  
The current study had several strengths. It was a randomized, longitudinal, controlled cohort 
study carried out at multiple sites in Rwanda. Compliance with the study treatments was 
documented by direct observation by study staff. Retention of participants in the study was high 
and did not differ between study groups. Furthermore, the objective outcome measures were 
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systematically assessed and documented. Limitations of the study were the absence of a placebo 
arm, and neither participants nor study staffs were masked to treatment allocations. Also, there 
was no control group without ART or an HIV-negative group. The study had other design 
weaknesses, such as a lack of data collection on concomitant treatments such as cotrimoxazole. 
Also, adverse events to the drug therapy that were not severe enough to cause participants to 
withdraw from the study, were not recorded. Data on the duration of ART was not collected and 
therefore could not be adjusted for in the multivariable regression model for changes in CD4 
levels across pregnancy. The study was not developed to investigate drug-drug interactions, and 
therefore such effects could not be confirmed. In addition, the analysis of the 3 sub-groups was 
not planned before initiation of the study and therefore no power analyses were performed. It is 
therefore possible that this sub-group analysis was not powered to detect more subtle differences 
between the groups. However, despite this, significant and important differences were noted. 
Our findings suggest that ABZ treatment of HIV-positive pregnant women is of benefit, without 
a need for screening for helminth infection. Thus, within regions where helminths are endemic, a 
non-targeted intervention may be more efficient than a targeted approach. However, the 
suggestion of a drug-drug interaction between ABZ and Coartem must be further investigated in 
pharmacokinetic studies. The present study shows the beneficial effects of ABZ therapy on viral 
loads, CD4 counts and serum haemoglobin levels, especially in women who carry helminth 
infections. However, there is some evidence that the effect on CD4 counts may not be entirely 
due to helminthic clearance, and requires further investigation. The very significant effect of 
ABZ therapy on CD4 counts and viral loads on subjects already receiving ART is an important 
finding, particularly in the light of results from previous studies where no beneficial effect of 
ABZ was observed in HIV-positive subjects not receiving ART [58,85,176,238]. Future studies 
must therefore compare the effect of ABZ on immune reconstitution in helminths-infected, HIV-
positive participants receiving or not receiving ART. Furthermore, a cost benefit analysis of 
targeted versus untargeted helminth treatment programmes is warranted in a large controlled 
study. The equal effectiveness of these methods in reducing helminth infection rates has been 
shown in the current study however, it is essential to determine whether there is any cost benefit 
for one of the treatment methods, particularly in light of the poor resource settings in which such 
programmes would be initiated. 
E. Ivan PhD thesis  Page 78 
 
Chapter 6: Discussion, Limitations, Conclusions, Recommendations 
and Future work 
 
6.1 Introduction 
This chapter summarizes the results of the whole study by highlighting the key points in a 
consolidated table, with a summary of the results presented in chapters three, four and five of the 
thesis. There is a further discussion of the study limitations encountered, the findings from each 
set of objectives, implications for key findings, conclusions drawn from the findings, and 
suggestions for future studies  
6.2 Hypotheses 
Hypotheses: The hypotheses from this thesis tested were as follows:  
I. Helminth-malaria dual infection and helminth infection prevalence is higher among HIV 
infected pregnant women on ART in Rwanda in rural compared to urban health centres. 
II. Malaria–helminth co-infection and helminth infection risk negatively correlate with 
socio-economic status of the HIV-infected pregnant women on ART in Rwanda. 
III. Deworming has a positive effect on HIV /AIDS immune progression markers among 
HIV infected pregnant women on ART in Rwanda. 
IV. De-worming using a targeted or a non-targeted approach is equally effective at reducing 
helminth infection levels. 
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6.3 Summaries and consolidation of findings reported herein 
Table 6.1. Consolidation of findings 
OBJECTIVE OF THE STUDY CHAPT. EVIDENCE FROM THE RESULTS 
Determining the prevalence of 
helminth-malaria co-infection 
among HIV+ pregnant women in 
rural and peri-urban settings in 
Rwanda and effects of 
antiretroviral therapy. 
3 
38% of individuals harboured helminths, 
21% had malaria; and 10% were co-infected. 
Prevalence of helminths and malaria was greater 
in the rural than in peri-urban populations. 
The most prevalent helminth species were 
Ascaris lumbricoides (20.7%), followed by 
Trichuris trichiura (9.2%), and Ancylostoma 
duodenale and Necator americanus (1.2%). 
Helminth infections were characterized by low 
haemoglobin and CD4 counts. 
In multivariate analysis subjects treated with a 
d4T-3TC-NVP regimen had a reduced risk of 
Trichuris trichiura infection (OR, 0.27; 95% CIs, 
0.10-0.76; p<0.05) and malaria-helminth dual 
infection (OR, 0.29; 95% CI, 0.11-0.75; p<0.05) 
compared to those receiving AZT-3TC-NVP 
Describing helminthic and malaria 
infection levels and risk and 
protective factors in HIV-infected 
pregnant women on antiretroviral 
therapy in Rwanda 
4 
Helminth infection was more prevalent in rural 
than peri-urban settings. 
Poor education and unemployment were risk 
factors for both helminth and P. falciparum 
infection, whilst hand washing protected against 
worm infections. 
In multivariate logistic regression analysis of 
data, HIV treatment with AZT-3TC-NVP was 
associated with a lower risk of helminthic 
infections. 
A CD4 count ≤ 350 cells/mm3 was associated 
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OBJECTIVE OF THE STUDY CHAPT. EVIDENCE FROM THE RESULTS 
with higher levels of helminthic and malaria 
infections. 
Multiple linear regression analysis demonstrated 
that helminth egg counts (EPG) were highest in 
multigravid women.  
Haemoglobin levels were lowest in women who 
had helminthic or malaria infections. 
The effect of deworming on 
immune markers of disease 
progression among HIV-infected 
pregnant women on ART. 
A longitudinal study of two anti-
helminth treatment arms: targeted 
and untargeted 
5 
Anti-helminthic therapy showed a significant 
effect on: helminthic prevalence rates, Hb levels, 
CD4 cell counts, and viral load detection.  
The prevalence levels of individual helminthic 
infections at baseline for the total cohort (N=980) 
were as follows: A. lumbricoides, 20.8%; T. 
Trichiura, 7.14%; hookworm species, 6.33%. 
The prevalence of P. falciparum infection was 
similar at all time-points for the two treatment 
arms, with a significant fall in prevalence by visit 
2 in both arms. 
However, there was a tendency for the infection 
rate to be higher at visit 4 in the non-targeted 
arm: 7.8% vs. 5.1% (p=0.09). 
The prevalence of helminthic co-infection with P. 
falciparum was significantly (p<0.05) higher in 
the targeted (8.60%) compared to the non-
targeted group (4.90%) at baseline, but in both 
groups no co-infection was detected at any of the 
subsequent visits. 
Haemoglobin levels were similar in both arms at 
all study visits, rising significantly from visit 1 to 
visit 2 in both arms and peaking by visit 3. 
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OBJECTIVE OF THE STUDY CHAPT. EVIDENCE FROM THE RESULTS 
Thereafter, levels fell significantly for visit 4. 
The CD4 counts rose significantly (p<0.0005) 
from visit 3 to visit 4 in the H-all ABZ+all group 
leaving levels significantly (p<0.05) higher than 
in the H+ABZ+ group. 
The loss of a P. falciparum infection or any type 
of helminth infection between study visits 1 and 2 
was associated with a significant increase in CD4 
counts and haemoglobin levels (for worm 
infections only). 
6.4 Malaria and helminthic co-infection among HIV-positive pregnant women: prevalence 
and effects of antiretroviral therapy 
6.4.1 The preliminary prevalence study 
The aim of the pilot study was to determine the prevalence of helminths and malaria dual 
infection in the study population of HIV infected pregnant women on antiretroviral therapy. The 
pilot study was to guide validate study tools before commencing the large longitudinal study. We 
found that the prevalence of helminthic and malaria co-infections is high among HIV-positive 
pregnant women in rural than urban population settings in Rwanda. Earlier study indicated that 
malaria and helminth infections are co-endemic and constitute disease burdens of major public 
health importance [152,239]. The study results have indicated that helminthic infection in this 
population is an important risk factor for low haemoglobin and CD4 cell counts as presented in 
chapter 3, whilst malaria-helminthic dual infections are characterized by a reduced BMI. The 
high burden of parasitic infections with high co-infections sited in pregnant women in Rwandan 
population, have implications for more immunological studies needed. This study further adds on 
existing body of knowledge for the overlapping co-endemicity nature of these parasites with 
HIV-1 and is common in most other East and central African countries where helminths and 
malaria co-exists [59,70,239,240]. Ladner et al in a prospective study in Rwanda documented the 
association between malaria and maternal HIV infection and concluded the increased risk of 
malaria occurrence in all HIV-infected women [167]. In our study both helminths and malaria 
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were common in rural than peri urban settings similar to another study conducted in eight 
districts among school going children for prevalence of helminths. Our results are in agreement 
with data from Rwanda secondly education students [19], which showed that intestinal parasites 
of public health relevance are prevalent among students attending tertiary schools. The 
importance of living and eating in hygienic environments as well as drinking safe water is 
important and all efforts need to be strengthened in children and in adults leaving in poor 
resource settings [241,242]. This implies that there is a clear need to strengthen the deployment 
of existing malaria and HIV prevention and intervention measures for pregnant women as 
reported by many other studies on the burden of co infection of these ailments with HIV in poor 
communities [243–247]. Early systematic review commends improved hygiene as important 
tools to combat helminthic infections among risky population groups [248]. The overlapping 
nature of helminths, malaria among HIV infected pregnant women calls for strategies of control 
in similar settings [59,239]. This part of thesis data concludes that co-infection of helminth and 
malaria was common among pregnant women taking antiretroviral drugs mainly from rural than 
urban settings. Of particular interest, certain ART regimens seem to have positive effects on both 
Plasmodium falciparum and Trichiura trichiura infections, and further studies need to be 
undertaken in large prospective cohorts and trials to confirm and further specify these results 
6.5 Helminthic infection and malaria in HIV-infected pregnant women on anti-retroviral 
therapy in Rwanda 
6.5.1 The prevalence, risk and protective factors study 
The intervention data of this study aimed to determine the actual helminth and malaria infection 
rates among HIV infected pregnant women on antiretroviral therapy. This is presented in chapter 
4 of the thesis as earlier described. Thus the findings were in agreement with the preliminary 
prevalence study showing that co infection rates was higher among women dwelling in rural than 
per -urban settings [205]. This clearly indicates that co-infection with diseases of poverty can 
severely affect the poorest rural population and therefore the strategy to control these infections 
should purely involve use of existing anthelminthic drugs that are effective as reported in most 
existing literature [72,92,108,200,249,250]. Like in most other studies, in this study use of 
anthelmintic therapy is highly recommended in such populations [200,251] but because re 
infection typically occurs more frequently, in this thesis it is further recommended that integrated 
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control approaches should utilise health education tools to interrupt transmission of these 
ailments as reported in similar studies [45]. This study furthermore indicated that hand washing 
and improved sanitation reduced infection rates that concurs with earlier studies recommending 
improved sanitation to reduce helminth infections [20,45,92,200,248,252]. Co-infection of 
helminth and malaria prevalence and risk of infection with each was common in this study but 
like most other studies the effect of helminth co infection on malaria in human still remain not 
conclusive [75,104,253]. However, more studies are required to find out how interaction of 
helminth or malaria could contribute to increased prevalence of malaria infection or vice versa in 
populations where co-endemicity is common as earlier reported in evaluation study to measure 
the association [76,188,254].  
The findings on effect of antiretroviral drugs on malaria and helminthic infection rates were 
found very interesting. Whilst there is a limit to the interpretation of the findings, they warrant 
further investigation. Although the ART-induced reconstitution of cellular immunity would 
probably be the main factor for reducing helminthic infections among HIV patients [78,94], 
previous in vitro and in vivo investigations indicated that HIV treatment, especially with protease 
inhibitors (PIs), could have a direct effect in killing off parasites, including those causing malaria 
[179]. It has been proposed that ART without PIs may reduce the prevalence of helminthic 
infection [255]. Thus, ART itself might have contributed to the decline in the helminth 
prevalence, asymptomatic malaria or co-infection seen in our study as previously reported in 
other studies [70,125,239]. We hypothesize that the anti-mitochondrial toxicity of ART 
compounds may play a direct role here, a hypothesis for which support needs to be gained from 
further in the field trials, designed to address this question. 
To summarize, the findings from this study lead the author to suggest that HIV-positive pregnant 
women would benefit from the scaling-up of de-worming programs alongside health education 
and hygiene interventions. But further studies need to be conducted regarding the findings on the 
differential effect of certain ART combinations, as observed most strongly with AZT-3TC-NVP, 
possibly protecting against helminthic infection and rule out possible drug–drug interactions
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6.6 Effect of deworming on immune markers of HIV-1 − disease progression among 
pregnant women on ART: targeted versus untargeted longitudinal groups 
6.6.1 Implications for STHs management and control policies at local and national levels 
Deworming can be a helpful tool in control programs targeting helminths, malaria co infections 
in HIV/AIDs patients on ART. In this study we have shown that immune markers of HIV disease 
progression such as viral load and CD4 Cell levels can be boosted with anthelminthic use along 
with specific ARTs and have also shown positive impact on haemoglobin levels. Previous 
studies among pregnant women had indicated similar trends suggestive of significant benefits in 
population subgroups but with varying results in other groups of different settings 
[123].However, there are biological reasons to believe existence of such benefits and this has 
been earlier reported [123,125,200] 
Our results have shown that certain ART combination therapies have significant effect on 
prevalence of helminths and malaria helminth co infection rates. Implying that in places where 
co infection is common, selection of ART combination is important to control helminth co 
infection while deworming of pregnant women is encouraged. Several investigators have 
indicated that deworming is of potential benefit to the pregnant women [13,75]. In ART eligible 
Pregnant HIV-infected women, ART helps in virological suppression [256–259]. Specifically, 
AZT-3TC-NVP, AZT-3TC-LPV-r, and AZT-3TC-ABC have been shown to decrease MTCT 
[260]  and more benefits have been suggested by new ART guidelines suggesting a switch to 
earlier ART initiation by world health organisation guidelines [261–264] and this approach 
supports innovative efforts towards total viral suppression [262]. In many countries aiming 
towards the goal of eliminating mother-to-child transmission of HIV [265–267] and our study 
results were generated among women who initiated ART early and benefits for deworming was 
found very significantly beneficial on Viral load, CD4 and hemoglobin levels. Future studies 
should explore the role of ART combination therapies in the management of haemoglobin levels 
to control the effects of anaemia in helminthic-malaria co infections in other longitudinal studies 
specific for this purpose. This would elucidate the immunological mechanism associated with 
increase in CD4 levels and viral load suppression and combined effects of worm removal. 
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The results of this thesis have the potential to inform the local and national health policy 
managers to strengthen the use of anthelminthic during pregnancy, and to extrapolate it to other 
services such as those for non-pregnant women. Targeting the control and treatment of HIV-1 
co-infections with helminths, malaria and other NTDs in Rwanda and link it to existing 
antiretroviral therapy programs.  
It can be suggested that the relationship between helminths with malaria is particularly very 
important strategy that further supports disease integration. Therefore, combined control 
programs are likely to explore more opportunities to enhance control efforts and diagnostics 
central to this joint approaches to fight a global war against these parasites targeting poor 
population as reported by other studies [250]. The results presented in chapter 5 of this thesis 
shed more light on whether mass treatment (untargeted-deworming) or diagnosis and subsequent 
treatment of helminthic infections (targeted deworming) should be part of routine HIV care 
within antenatal and prevention of mother to child transmission (PMTCT) services. 
This thesis has ground reasons to incorporate periodic deworming, using albendazole, into 
existing ANC and PMTCT programs as a single package that is less costly and more effective for 
resource-limited communities where co infection with HIV-1co-exists. The benefits of this 
intervention approach would improve haemoglobin levels and thus the control of anaemia, which 
is commonly associated with both malaria and helminths during and after pregnancy, and would 
improve immunological response to ART. The fact that certain ART combination therapies 
seemed to reduce the prevalence of helminth infection in the co-infected populations suggests 
that, in areas where co-infection is common, selection and prescription of particular ART 
combinations could be considered along with use of albendazole.  
The timing of deworming is also an important consideration during the implementation 
programs. In our study, albendazole was given to women every 12 weeks and re-infection rates 
were reduced considerably, which implies that deworming is relevant and more effective when 
given routinely but with repetitive dosage after about 12 weeks. The effect of anthelminthic on 
HIV viral load detection and CD4 cell count levels that rose when subjects were given 
albendazole without helminthic infections is indicative that anthelminthic actually can have an 
effect on subjects’ immunity independent of their anti-helminthic effect. 
E. Ivan PhD thesis  Page 86 
 
6.7 Strength and weakness of the study 
While conducting the pilot primary prevalence study, the conclusions were striking. However, 
the sample size used to test the effect of ART on specific helminth infections and malaria was 
relatively small so that the effect of sample size might have reduced the significance of the 
conclusions.  
In the second study the baseline intervention data again suggested an effect of ART on helminth 
infection but the ART regimen that was most effective in the pilot study was not so in the 
baseline study. This might imply a mass effect of ART compounds on helminth infections, which 
would call for further longitudinal studies to specifically analyse these effects for reproducibility. 
The current study was not primarily designed to look for the effect of ART on helminth 
prevalence rates and malaria infection. Certain ART combinations showed a differential effect 
on helminthic infections and, specifically in the study reported in chapter 3, where the d4T-3TC-
NVP and the AZT-NVP regimens both had a significant effect on the risk of helminth infection 
when compared to the reference ART regimen (AZT-3TC-NVP). These results were in stark 
contrast to those reported in chapter 4 where the AZT-3TC-NVP regimen had the strongest effect 
on helminth infections.  
The unexpected differences observed between these two studies may be due to differences in 
sample size, or may be due to other uncontrolled confounding factors. Thus, in the social 
demographic case report form used, described in chapter 2 we did not capture the different drugs 
which the women were using or had used, particularly the reported prophylactic combinations of 
routine drugs such as cotrimoxazole [51,125,128,216], which is very commonly used in PMTCT 
routine programs, and which might have differential effects on the level of opportunistic 
infections such as malaria in HIV-infected individuals that has been reported in several other 
studies [51,70,239]. This is a hypothesis, which needs to be explored further and a limitation to 
this analysis. However, the data provided here is important and opens up ideas for future studies 
regarding the role and effect of ART combinations on helminthic and malaria co-infections in 
HIV infected populations. 
The influence of confounders and spatial factors that might have affected our results cannot be 
ruled out, given the lack of specific control groups and failure to consider independent effect of 
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cotrimoxazole on malaria and helminths in our setting. Subjects in the study were recruited via 
antenatal care (ANC) routine settings and health centres with PMTCT services in rural and peri-
urban community facilities, and was randomly assigned to two groups, ‘targeted’ and 
‘untargeted’ intervention arms. These may nonetheless be biased, which would affect the 
generalizability of findings beyond the study population.  
The HIV-infected pregnant women represented Rwandan rural and peri-urban residents utilizing 
PMTCT/ANC services, and did not include those in the first trimester of pregnancy or even 
include recent migrant users of the free ANC/PMTCT services existing in Rwanda. Therefore, 
the sample may not be sufficiently representative of contemporary Rwandans 
It can also be argued that few rural and peri-urban sites were sampled, due to logistical problems 
at the time the study was conducted. Thus the study did not sample women living in all parts of 
the country. The thesis findings therefore cover only specific sub-populations within Rwanda, 
and it remains speculative whether these data on prevalence can be extrapolated to other areas. 
However, these data highlight the importance of conducting similar studies in different settings 
and different population groups 
Two of the studies were cross-sectional in nature, so that we cannot prove causality for any 
association described in those studies. Within the longitudinal study, all immune markers of 
disease progression, like CD4 cell counts, viral loads and haemoglobin levels were measured at 
intervals of 12 weeks over a period of one year. This is still too short a time for following up 
measures of association and predictors of this nature, and thus may not be indicative as markers 
for long-term status. It would have been better to take measurements for at least two years or 
longer, but lack of funding was a limitation to elucidate this hypothesis. 
Further limitations of the study were the absence of a placebo arm, and neither participants nor 
study staffs were masked to treatment allocations. Also, there was no control group without ART 
or an HIV-negative group. Additionally, the Kato Katz method used to determine the number of 
helminths eggs could have underestimated the proportion of women with light hookworm 
infection. 
Our intervention study cohort had several strengths. It was a randomized, controlled 
observational cohort study carried out at a number of sites in Rwanda. Compliance with study 
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treatment was documented by direct observation by study staff. Compliance with treatment was 
shown by a dramatic fall in helminths infections from the first to the final visit. Retention of 
participants in the study was high and did not significantly differ between study groups. 
Furthermore, the objective outcome measures were systematically assessed and documented. 
Compliance with the study treatments was documented by direct observation by study staff. 
Retention of participants in the study was high and did not differ between study groups. 
Furthermore, the objective outcome measures were systematically assessed and documented. 
Additional strengths of this study are the screening of 3 stool samples on consecutive days for 
the presence of helminths, and the use of a combination of two different screening techniques to 
increase the sensitivity of helminths and malaria diagnosis. The strengths of this study also 
included the screening of a large number of women from health centres, which cater for women 
of all socio-economic classes.  
6.8 General conclusions and recommendations from the thesis 
6.8.1 The prevalence and effect of antiretroviral therapy at baseline 
This study shows a high prevalence of malaria and helminthic infection among HIV-positive 
pregnant women in Rwanda.  
Helminthic and malaria infection during pregnancy in HIV-infected individuals may lead to 
serious consequences for mother and baby. It is possible that such findings can inform policy-
makers in better planning for interventions and analysis of the effect of infections in health 
outcomes. This study showed that more infections occurred in rural than in peri-urban settings. It 
is important that future interventions should be targeted to rural communities rather than urban 
settings, with health education and sensitization programs to promote individual hygiene in the 
rural settings. Antenatal care service interventions for malaria, HIV/ AIDs and helminth control 
should continue to be promoted in these settings, and women coming from rural settings with 
higher helminthic infection rates should be provided with treatment opportunities with available 
drugs and should also be offered health education to enhance self-hygiene practices in their 
communities.  
The information obtained in these studies can be used to plan longer-term interventions, target 
higher-risk women and integrate interventions for co-infections in existing health infrastructures 
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the better to mitigate the impact of infections in pregnancy. The findings demonstrate that 
demographic and socioeconomic risk factors may play a role in co-infection exposure. Our 
findings can be used to guide public health interventions and also identify potential confounders 
to be considered during further analysis of the effects on health outcomes of these infections in 
pregnancy. We recommend that future interventions to control HIV and malaria in ANC settings 
should be integrated with deworming to control and treat helminthic co-infections in pregnancy, 
targeting mostly rural settings and peri-urban locations, while utilizing ANC/PMTCT 
infrastructure. This can be extrapolated to non-HIV pregnant women in similar settings.  
6.8.2 The differential effect of ARTs on the risk of helminthic infection  
In areas endemic of helminthic infection, tuberculosis (TB), malaria and HIV are to a large 
extent overlapping [59,239]. This is in agreement with a study in Ethiopia, on co-infection 
involving the ‘big three’ diseases (HIV, malaria, TB) were conducted in which a third of smear-
positive TB patients were infected by helminths. This implies that co-infection by HIV, TB and 
malaria is likely to carry helminths along. In the same study, threat of worm infection declined 
during TB treatment in HIV+/TB co-infected patients, whereas no decline was seen in HIV−/TB 
group. This implies that, when co infection is treated, the intervention gain is likely to be two- or 
three–fold. 
6.8.3 Prevalence, risk and protective factors 
ART without PIs may reduce the prevalence of helminthic infection. Thus, ART itself might 
contribute to the decline in helminth prevalence, asymptomatic malaria or co-infection, as seen 
in our study. Although immune reconstitution might be praying a role [94], we hypothesize that 
the anti-mitochondrial toxicity of ART compounds may play a direct role here. The possible 
anti-helminthic effect of some ART combinations on helminths and malaria warrants further 
study.  
This data leads us to suggest that the prevalence of helminthic infections, malaria and co-
infections is common in HIV-positive pregnant women on ART in Rwanda. Helminthic and 
malaria infection in this population are important risk factors for low haemoglobin levels. 
Subjects with low CD4 counts were at higher risk of infection, and helminthic infection is a risk 
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factor for malaria. Education and employment were independent protective factors for helminthic 
infection and malaria, whilst hand washing reduced the risk only for helminthic infections.  
In addition to the obvious recommendation to emphasize continuous health education and 
individual hygiene practice, there are increased opportunities for generating income, in the 
making and selling of soap to improve hygiene and to reduce helminthic transmission; this could 
also extend to malaria-control devices such as insecticide-treated nets (ITN).  
Particularly with regard to the conclusions related to the indications of deworming during 
pregnancy for women infected with HIV and on ART, we recommend measuring haemoglobin 
as a key indicator of maternal and neonatal health. This provides a rationale for having PMTCT 
services integrated into maternal, newborn and child health services, as a cost-effective approach 
6.8.4 Effect of deworming on markers of disease progression 
Life saved with availability of ART is commendable but HIV patients often get opportunistic 
infection, which deteriorates the health of infected patients. In sub Saharan Africa, co-infection 
with HIV and helminths is very common. Deworming with albendazole has been recommended 
very effective even in pregnant women. Our findings demonstrated that Deworming with 
albendazole (400mg) in HIV-infected pregnant women on antiretroviral therapy demonstrates a 
significant positive impact on HIV viral load between visit 1 and visit 4. This has important 
implications for the control of anaemia in pregnancy, which is very common in helminthic and 
malaria infections and may lead to problems for both the mother and the baby. Additionally, this 
again points out a vital implication on viral load as a best surrogate marker for disease 
progression and prognosis, which should be used while monitoring of HIV patients on ARTs  
We recommend that the treatment of these co-infections should be integrated into the routine 
HIV CD4 cell count testing programme, and HIV viral load detection profiles may be used as 
surrogate markers of co-infection in the national health programmes where resources are limited.  
Further studies are recommended to examine the effect of specific ART combinations on 
helminths so as to select ART regimens during helminthic co-infections. There may be important 
alternative approaches for delaying HIV /AIDs disease progression in the course of applying de-
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worming methods. Further studies are also suggested to rule out role of drug-drug interaction in 
such cases 
6.9 Suggestions for further research 
The findings in the first paper show that the study population has a moderately high prevalence 
of helminth-malaria co-infections.  Further studies are warranted, using different populations to 
monitor the immunological response to co-infection and to its treatment.  
The beneficial effect of anthelminthic treatment on hemoglobin levels, viral load detection rates 
and CD4 cell trajectories observed in the third paper warrants further studies in controlled, 
randomized clinical trials for different population groups. 
The observed benefits of de-worming on immune markers of HIV disease progression in the 
targeted and untargeted de-worming arms is impressive, and the  analysis of cost-effectiveness is 
recommended to be carried out to determine which of these therapies has the best cost-benefit 
outcomes. 
The mechanisms by which certain ART combinations affect helminth infection levels calls for 
further work to confirm these results. In addition, possible drug-drug interactions between 
albendazole and Coartem must be analysed in future studies. 
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Appendix 3: Questionnaire (CRF) 
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Appendix 4: Follow up form (FU) 
 
SUBJECT TEL: _______SUBJECT ID:    
FOLLOW UP POST TERM VISIT #4: 
Date: ____/______/__________ 
Physicals: ____________________ 
 Weight/Kgs: _______________ 
 Height/m2: ________________ 
BMI: ____________Compliant With Meds: ___Yes ___No 
Malaria Smear:   
 Positive:  ___Yes   ___No__ 
 HRP-2 Positive: Yes___ No__ 
Stool Smear: Yes__ No__ epg__Worm type___CD44:___/Viral 
load2:___Hb4/gdl_______ 
FOLLOW UPVISIT #2: 
Date: ____/______/__________ 
Physicals: 
Weight/ kgs: ____________________ 
Height/m2:_______________ 
BMI: ____________Compliant With Meds: ___Yes ___No 
Malaria Smear:  Positive:  ___Yes   ___No___HRP-2 positive: 
Yes__ No__ 
Stool smear positive: Yes__/No___ _ epg___ 
Worm type______CD42:_____Hb2/ gdl_____ 
 
FOLLOW UP VISIT #1: 
Date: ___/__/____Age__ Trimester__ 
Physicals: Weight/ kgs: _________________ 
Height /m2: ____________BMI: _____________________ 
Compliant With Meds: ___Yes ___No 
Type of ARV__ Duration on ARV___ 
Malaria Smear:  Positive:  ___Yes   ___No 
HRP-2 Positive: Yes -----No__Stool Smear: positive: Yes__ 
No__ epg ____Worm 
type________CD41:___Viralload1:______Hb1/gdl_____ 
FOLLOW UP POST TERM VISIT#3: 
Date: ____/______/__________ 
Physicals:  
 Weight/Kgs: _______________ 
 Height/m2: ________________ 
BMI: ___________Compliant With Meds: ___Yes ___No 
Malaria Smear:   
 Positive:  ___Yes   ___No 
 HRP-2 positive: Yes__ No___ 
Stool Smear: Positive: Yes__ No___ epg___Worm 
type_______CD43:____HB3/gdl___ 
Helminths-HIV STUDY Follow-Up Form 
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Appendix 5: Published paper with Acta Tropica  
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Appendix 6: Published paper with PLOS NTDs 
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